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Abstract 
Breast cancer is the most common cancer seen in women worldwide 
accounting for more than 1 .3 mill ion cases and 458 000 deaths a year worldwide. 
Breast cancer patients are at high risk of recurrence in the form of metastatic 
disease. Genes associated with invasion and metastasis provides an aggressive edge 
in proliferation and growth during colonization of the metastatic site. The 
SMARCAD 1 (SWIIS F-related, Matrix-associated Actin-dependent Regulator of 
Chromatin, containing DEADIH box I )  protein is the human homolog of yeast 
Fun30 (Function Unknown Now 30) proteins. These proteins are members of the 
Snf2 hel icase motif-containing protein families, and are known to act as ATP­
dependent D A translocators. Previous studies have shown that yeast Fun30 
deletions are resistant to ultraviolet (UY) radiation. The over-expression of Fun30 
has been shown to affect chromosome stabi l ity ,  integrity , and segregation. Fun30 
has also been shown to be a potential cyclin-dependent kinase (Cdk l )/Cdc28 
substrate. The SMARCAD 1 is a DEADIH box-containing helicase which includes 
proteins essential for repl ication, repair, and transcription. In addition to two 
DEADIH box and an ATP-binding motifs within SMARCAD l ,  it has a putative 
nuclear local ization signal and several regions that may mediate protein-protein 
interactions. Expression analysis indicates that SMARCAD 1 transcripts are 
ubiquitous, with particularly high levels in endocrine tissue. The gene for 
SMARCAD 1 has been mapped to the chromosome 4q22-q23m, a region rich in 
break points and deletion mutants of genes involved in several human diseases, 
notably soft tissue leiomyosarcoma, hepatocellular carcinoma, and hematologic 
mal ignancies. It has been recently reported that the binding sites of endogenous 
SMARCAD 1 IKIAA I 1 22 are frequently found in the vicinity of transcriptional start 
sites. Moreover, human SMARCAD I overexpression was observed in E I A­
expressing cel l l ine with increased capacity for gene reactivation events by genomic 
rearrangements suggesting that human SMARCAD 1 may play a role in genetic 
instabi l i ty .  Previous studies in our laboratory showed that the breast cancer cells 
estrogen receptors (ER)-negative MDA-MB-23 1 and MDA-MB-23 1 - 1 833  as well 
as ER-positive MCF-7 and T47D express a high level of SMARCAD I in 
comparison with the nonnal breast epithelial cells NHME. 
In my master research project, we investigated the impact of specific 
si lencing of S MARCAD I on human breast cancer cell proliferation, colony growth, 
morphology , migration and invasion using human breast cancer cells estrogen 
receptors (ER)-negative M DA-MB-23 I .  
In this respect, the cells were stably transfected with two different designs 
of SMARTvector 2.0 Lentiviral shRNA partic les targeting SMARCAD l .  Control 
cells were transfected with SMARTvector 2 .0 Non-Targeting control particles. 
The positive c lones ( 1 0  to 1 2  from each design) were selected under puromycin 
and the GFP positive c lones were analyzed using western-blot to confirm specific 
SMARCAD I silencing. The two different design of shRNA targeting 
SMARCAD I induced 99% decreased in the SMARCAD 1 protein level 
(SMARCAD 1 -shRNA l ,  and SMARCAD l -shRNA3).  The selectivity of this 
silencing was confirmed by the fact that no impact on SMARCAD I protein was 
observed in the cells transfected with shRNA-conh'ol particles (control-shRNA). 
We demonstrated for the first time that silencing of SMARCAD I resulted in a 
xi 
significant inhibition of cel lular proliferation and colonies formation in soft agar, 
as well as cel lular migration, and invasi eness. All together, these results strongly 
suggest that SMARCAD 1 may play an important role in breast cancer growth and 
metastasis. 
Identi fication of new molecular effectors and signaling pathways involved 
in breast cancer growth, invasion, and metastasi s  could lead to effective targeted 
approaches in breast cancer therapy . 
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1. Brea t Cancer 
Breast cancer is a tumor that forms in the mammary glands, most commonly 
from the inner l ining of milk ducts or the lobules. It can affect both male and 
female; however, breast cancer in male, is rare. 
2. Breast Cancer Epidemiology 
2.1. Worldwide 
Breast cancer is the second most common cancer in the world after lung 
cancer. It is however, the most common cancer worldwide in women with 1 .38 
mil lion cases of breast cancer (23% of total cancer burden) in 2008. Breast cancer 
is the fifth cause of death from cancer overall (458 000 deaths), but it is still the 
most frequent cause of cancer death among women worldwide [ 1 ] ,  [2] .  One in nine 
women is estimated to develop breast cancer in her l ifetime, and I in 29 is 
expected to die from it [3 ] .  About 50% of the breast cancer cases and 60% of the 
deaths are expected to occur in developing countries. Western countries have the 
highest incidence rates, but lowest death rates. Some of the factors that added to 
the international variations in the incidence rates are largely the differences in 
reproductive and hormonal issues and the accessibil ity of early detection services. 
Recent use of postmenopausal hormone therapy or late age at first birth are 
considered reproductive factors that increase the risk of breast cancer. Alcohol 
consumption also increases the risk of breast cancer [2] . 
2.2. U A E  
Cancer IS the third leading cause of death in  the UAE fol lowing 
cardiovascular diseases and accidents. Data from the UAE Ministry of Health 
point out that cancer accounts for approximately 500 deaths per year. Increasing 
2 
numbers of young women being detected with breast cancer, debunking earlier 
findings that women above 45 were more prone to the disease, according to 
HAAD's breast cancer awareness team. Breast cancer accounts for 28 per cent of 
all female deaths in the UAE. Previously women in their 40s and above were 
affected [4 ] .  Unfortunately, over the past few years an increasing number of 
women in their early 30s and 20s were diagnosed with breast cancer due to the 
adoption of a Western l ifestyle -- which primarily manifests itself in an increased 
intake of high-calorie food -- and lack of awareness on how to seek early 
treatment. Statistics show that 1 60 women develop breast cancer every year in Abu 
Dhabi alone. Breast cancer occurrence rates are very low among women below the 
age of 25 . After this age, the incidence rate stads to rise. For example, roughly 
about one quader of the breast cancers occur in the age group of 25 to 49 years, 
one quader in women of 50 to 59 years of age, and the incidence peaks in women 
over 60 years of age - almost half of the cases fal l  into this age category. Even 
though the number of cases is increasing, the overall modal ity due to breast cancer 
has decreased. Mostly, this is attributed to early detection and advanced treatment 
possibi l it ies [3] .  
3. B reast Cancer Risk Factors 
With regards to breast cancer, every woman is at risk of developing this 
disease. However, knowing the risk factors doesn' t  tell us evelything. This does not 
mean that a female will  get the disease by having a risk factor, or even several risk 
factors. Most women who have one or more breast cancer risk factors never 
develop the disease, while many women with breast cancer have no obvious risk 
factors (other than being a woman and growing older). 
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The most well recognized risk factors for breast cancer are age and family 
history. The ri k of developing breast cancer increases by getting older and can be 
doubled every ten years, and at the age 70 breast cancer incidence can reach to 500 
cases per 1 00,000 women [5] .  About 1 out of 8 invasive breast cancers is 
established in women younger than 45 , whereas about two out of three invasive 
breast cancers are found in women at age 55 or older [6] . However, young women 
diagnosed with breast cancer have more aggressive tumors associated with poor 
survival prognosis [7] . 
The main risk factor for developing breast cancer is simply being a woman. 
Gender is by far the most important risk factor. Breast cancer occurs 1 00 times 
more regularly in women than men [8] .  The main reason why women develop more 
breast cancer is that women 's  breast cells are regularly exposed to the growth­
promoting effects of the female honnones estrogen and progesterone [9] . 
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Increase hormonal exposure in early menarche and late menopause is also 
considered as a risk factor. Early exposure to ionizing radiation, alcohol 
consumption, high breast density and some medications such as long-term 
postmenopausal honnone, like estrogen replacement are sti l l  controversial risk 
factor for breast cancer [ 1 0] .  
3.1. Hormonal factor 
In postmenopausal women, elevated levels of some honnones, like estrogen 
and androgen, are associated with increased risk of breast cancer [ 1 1 ) .  Females that 
have early menarche or late menopause have more menstrual cycles and this  leads 
to longer exposure to estrogen and consequently to increase the ri sk of developing 
breast cancer. So any stimulus that leads to increase in exposure to these hormones 
is considered as a risk factor for breast cancer. 
It has also been reported that women taking postmenopausal hormonal 
replacement therapy for five years or more have a high risk of developing breast 
cancer [ 1 2, 1 3) .  Several epidemiological and animal studies suggest that l 7�­
estradiol ( E2) is directly involved in breast cancer via an unknown mechanism. 
Two pathways are involved in estrogen carcinogenesi s :  E2 metabolism and E2 
estrogen receptor. 2-0H and 4 -0H catechol estrogens are two metabolites of E2 
that develop via phase I metabolism and oxidation. These metabolites cause DNA 
damage leading to cancer. In addi tion, via estrogen receptors, E2 can stimulate cell 
proliferation and gene expression [ 14) . 
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3.2. Dietary factors 
Several studies suggests an association between sunl ight exposure and low 
breast cancer occurrence and mortal i ty [ 15 ] .  Vitamin D, which comes as a result of 
exposure to the sunlight has anti carcinogenic properties ( 1 6) .  The biologically 
active form of vitamin D, the 1 ,25(OH)2D, has anti-proliferative and pro-apoptotic 
effects and promotes the differentiation of breast cancer cells [ 15 ] .  However, 
females with very dense breast tissue are at high risk of subsequent breast cancer 
[ 15 ]  . 
Additional ly, being obese increases the risk for developing breast cancer by 
30 to 50%. POlter and his colleagues revealed that obese patients show larger, more 
advanced, and aggressive tumors [ 1 7] .  This might be due to the increases in the 
production of estrogen through the activity of aromatase in breast adipose tissue 
[ 1 8] .  The increases in breast cancer risk and mortality have been mainly associated 
with the upper body obesity as defmed by the waist-to-hip ratio [ 1 9] .  Increased 
estrogen production in obese patients is associated with the increased risk of breast 
cancer and enhanced progression of ER + breast cancer [20] . Physical activity 
during adolescence may be particularly protective. However, minor differences 
were observed between physically active premenopausal women and sedentary 
women [2 1 ] .  
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3.3. Lifestyle  and Environ mental factors 
Smoking and alcohol consumption are also considered as risk factors. The 
growth of breast cancer cells could be enhanced by nicotine, which means that 
nicotine can be transported to the breast tissue via plasma l ipoproteins fol lowing its 
passage through the alveolar membrane, and directly contribute to the molecular 
mechanism of brea t carcinogenesis [22]. Comparing smokers to women who have 
never smoked or are not currently smoking but whose passive smoking exposure 
was unknown, the risk of breast cancer increased among the women who smoke 
cigarettes [23] .  However, another study showed l ittle or no association [24 ] .  
Women who are exposed to high doses of  radiation, mostly through 
adolescence, have an increased risk of breast cancer. This l ink has been noticed 
among women who received high-dose radiation for medical purposes [25 ] .  
Uncertainties remain about the effects o f  low dose chest X-rays, particularly in 
individuals at increased genetic risk. 
3.4. Genetic risk factors 
Cancer is caused by either alterations in oncogenes, tumor-suppressor 
genes, and/or microRNA genes [26] . Around 5 to 1 0% of breast cancer cases are 
thought to be inherited resulting directly from gene defects (cal led mutations) 
inherited from a parent. The risk of breast cancer is increased two- to three-fold in 
female with a family history of breast cancer [27] .  
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BRCAI and BRCA2: In normal circumstances, expression of these genes helps to 
avoid cancer and prevent the cells from growing abnormally. Deletions and 
inactivating point mutations in these two genes cause a significant increase in the 
risk of developing breast cancer [28] [29], [6] . BRCA I is located on chromosome 
1 7  and play a role in many cellular process such as maintaining genome integrity 
DNA repair and tumor transcriptional regulation and suppression. The percentage 
of women who develop breast cancer with mutation of BRCA I is between 50-80% 
[30] . BRCA2 is located on chromosome 1 3  and it is responsible for preventing cells 
from uncontrolled proliferation and in repairing DNA damage. The risk of breast 
cancer in mutated BRCA2 is about 60-80% [27] . Family history of breast cancer is 
a well-known risk factor for breast cancer; the risk can increase in flfst-degree 
relatives with an average of about twofold [3 1 ] .  In young women carrying gremlin 
mutations in BRCAl and BRCA2, breast cancer is l ikely to occur and often affects 
both breasts. Generally, tumors with BRCAI mutations are negative for estrogen 
and progesterone receptors. However, most BRCA2 mutations are positive for these 
hormone receptors. Cells with mutations in BRCAI or BRCA2 gene lack functional 
BRCA I or BRCA2 protein and have a decreased abil ity to repair damaged DNA 
and grow in an uncontrolled manner [32] .  
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PS3 tu mor uppre sor gene: the flrst tumor suppressor gene identified was the 
p53 gene [33] .  This gene is local ized on the short arm of chromosome 1 7  and it 
encodes a 393 -amino acid protein, which is expressed at very low Ie els in normal 
cells [34] . P53 remains the most frequently mutated gene in human cancers, about 
50% of people with cancer have their P53 gene mutated, with an overall frequency 
of 25% in breast cancer patients [33] ,  [35] .  The most aggressive forms of breast 
cancer have P53 mutations, which are remarkably frequent, and apparently among 
the key driving factors [36] .  The functions of p53 in normal circumstances are to 
inhibit the proliferation of abnormal cells, thus preventing neoplastic development. 
Activation of p53 signal ing pathway, which used to be on ' standby' mode under 
normal cel lular conditions, take place in response to cellular stresses, and several 
anticancer agents. The L i-Fraumeni syndrome can be caused by inherited mutations 
of the p53 and people with this syndrome have an increased risk of developing 
breast cancer, as well as several other cancers [29] . 
HER-2: The tyrosine kinase receptor HER-2 gene mediates critical signaling 
functions in normal and malignant breast epithelial cells. Approximately 20 to 25% 
of humans have an overexpression of HER-2 receptor, which can lead to breast 
cancer [37) . An aggressive clinical phenotype of breast cancer is related to 
overexpression of HER-2 that includes high-grade tumors, increased growth rates, 
early systemic metastasis, and decreased rates of overall survival. This HER-2 
overexpression can resul t  in changes in the biological features of breast cancer, 
including increased proliferation and motil i ty, suppression of apoptosis, higher 
invasive and metastatic behavior, and independence of steroid hormones [37) .  
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4. Type of breast cancer  
The female mammary glands have a role in both nourishing the offspring as 
well as offering irnmunologjcal protection to the newborn baby. Each breast ha 15 
to 20 lobes; each lobe has many smaller lobules which end in dozens of little bulbs 
that can produce milk. Thin tubes called ducts are linked to lobes and lobules and 
eventually lead to the main lactiferous ducts, which open in the nipple (Schema 1 ) . 
Fat, blood and lymphatic vessels occurring in each breast fil l the spaces between 
the ducts and secretory units. The lymph vessels lead to small bean-shaped organs 
called lymph nodes, clusters of which are found in the axil la and in many other 
regions of the body. 
_-\mpolla 





Schema 1: Anatomy of the breast 
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Subcutaneous fat of the 
breast 
Breast cancer can be classified into two types (ductal and lobular cancer) according 
to the structure of the breast affected by cancer. The most common type of breast 
cancer is ductal carcinoma (7 of every 1 0  women) fol lowed by lobular carcinoma 
( 1  of every 1 0  women). 
Breast cancer is also classified according to its invasive status. If the cancer is 
judged to be non-invasive, it is cal led "in situ", and the invasive breast cancers are 
referred to as " infiltrating" .  The term "in situ" is defined as the cancer that has not 
spread into tissue other than the one it started in [38] .  
4.1. Ductal carcinoma in situ DCIS. 
DCIS is a non-invasive breast cancer characterized by early-stage cell 
abnormal ities in the breast ducts. If  it is untreated, about 30-50% of DCIS progress 
to a more invasive types of cancer [39] .  Before 1 980, DCIS was rarely diagnosed, 
but now about 25 % of DCIS are diagnosed in the United States due to the progress 
in the diagnostic methods. DCIS can be classified according to phenotypic pattern 
of the cells (solid, cribriform, papillary, and micro-papil lary), tumor grade (high, 
intermediate, and low grade), and the presence or absence of granulomatous 
mastitis [40] . Breast cancer deaths l inked with DCIS are due to the subsequent 
development of invasive carcinoma or areas of invasion that were left undetected at 
the time of diagnosis. However, when properly treated, DCIS are cured. On the 
contrary, at least half of invasive carcinomas have developed metastasis at the time 
of diagnosis [8] .  
1 1  
4.2. I nfIltrati ng or inva i e breast cancer. 
This is an aggressive type of breast cancer, which metastasizes to different 
organs such as lungs and bones. 
4.3. I nfla mmatory breast cancer ( I BC). 
mc has a poor prognosis and presents with symptoms resembling an 
inflammation. The cancerous cell emboli block the lymph vessels, leading to rapid 
swell ing of the breast, skin thickness and nipple retraction with redness and 
persistent itching [4 1 ] . In the United States, IBC represent up to 6% of breast 
cancer patients [42] .  The 3-year survival rate for patients with mc was far lower 
(34%) than that for patients with other types of breast cancer (90%) [43] .  
Stage Grading 
0 Tis NO MO 
I T 1 *  NO MO 
l IA TO N l  MO 
T l  * N l  MO 
T2 NO MO 
l ID T2 N l  MO 
T3 NO MO 
Il IA TO N2 MO 
T 1 * N2 MO 
T2 N2 MO 
T3 N l  MO 
T3 N2 MO 
I I IB  T4 NO MO 
T4 N l  MO 
T4 N2 MO 
I I Ie Any T N3 MO 
IV Any T Any N M l  
Table 1 :  New TNM staging classification approved by 
AJCC [44] 
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5. Brea t cancer tage 
In order for the oncologist to design a treatment regimen for patient cancer 
taging I Important. In 2000 a breast cancer ta k force wa constituted to ad Ice 
Amencan Joint Committee on cancer to receive the sixth edition of cancer staging 
manual [44] .  With the new achievement in diagnosis and treatments in the field of 
brea t cancer, change were needed in the TNM- taging sy tem (Table 1 ). The 
tage of breast cancer depends on the size of the brea t tumor and whether it has 
pread to lymph nodes or other parts of the body. T refers to the primary tumor, N 
to the lymph nodes and M to the existence or ab ence of metastasis in other organs 
of the body. 
tage 0: refers to the non-in asive breast cancer in which cancer cells have not 
spread into neighboring breast tissue or outside the duct in case of DCIS or outside 
lobule in the case of lobular carcinoma in situ. 
Stage I :  the breast tumor is no more than 2 cm in diameter and the cancer cells 
have not spread to the lymph nodes 
Stage I I :  is divided into two subcategories I IA and l IB 
Stage I IA:  the tumor is no more than 2 cm in diameter and has spread to the 
auxil iary lymph nodes, or the tumor is between 2-5 cm in diameter and has not 
spread to the lymph nodes. 
Stage lI B :  the tumor is between 2 and 5 cm in diameter and has spread into the 
auxi l iary lymph nodes or larger than 5 cm in diameter and has not spread to lymph 
nodes. 
Stage I I I :  is subdivided into three categories: 
Stage IlIA occur in two main scenarios: 
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I .  The tumor is no larger than 5 cm in diameter but ha spread to auxiliary 
lymph node that grow together fomllng clumps. The cancer may also 
pread mto the cervical lymph nodes. 
2 .  The tumor i larger than 5 cm in diameter and the auxi liary lymph nodes do 
not adhere to each other or other tis ues. 
tage I I I B: the tumor can be of any size and it spread to the skin of the breast or 
chest wal l .  This stage may also include swel l ing of the breast and lwnps in the skin 
of the breast 0 inf lammatory breast cancer is considered at least stage l IIB .  
tage I I IC: the tumor can be of any size but i t  spreads to  the lymph nodes area 
above or below the cla icle , chest wall and indoor the skin of breast. 
tage IV: it is known as distant metastatic cancer, the last stage of breast cancer, 
the tumor can be of any size and cancer cells have spread to other parts of the 
body, such as the lungs, liver, bones, or brain. The 5year survival rate is 1 3% [8] .  
6. Breast cancer in va ion and meta tasis 
Metastasis is a complex process, starting from the migration and invasion of 
cancer cells into the nearby tissues and lymphatic circulation. To form new colonies 
at metastatic sites, breast cancer cells must have access to the circulatory system 
and proliferate in vital organs, such as lungs, bones, brain and l iver. In order to 
promote these steps of motil i ty and invasion, the tumor microenvironment has an 
essential role by either secretion of chemotactic factors, such as (chemokines, 
growth factors, and matrix metalloproteases, which are felt by cancer cell surface 
receptors including integrins, receptor tyrosine kinases and G protein-coupled 
receptors (GPCRs)) or by direct interact ions with stromal cells [45 ] .  
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el lular motility.' in asion in three-dimen ional extracellular matr ix (ECM) 
can be  explamed by the lamellipodium exten ion a t  the leading edge. This can lead 
to the formation of new focal adhe ions comple e secretion of urface protease 
in contact with ECM and focal proteoly is. The cell body contraction by 
actomyosin complexe will end up by cytoplasmic tail detachment and cell 
movement. Brea t cancer cells re pond to chemotactic signals by reformation of 
their cytoskeleton through Rho family of small GTPases members Rho, Rac, and 
Cdc42. Rho controls the stress fibers and focal adhesion formation, Rac regulates 
membrane ruffling and lamellipodia and Cdc42 regulates fi lopodia formation [45] .  
7. Pathogene is of b reast cancer: key genes and pathways 
Familial breast cancer involved two human genes B RCA I and B RCA2. The 
two B RCA genes serve as important regulators of cell-cycle "checkpoint control" 
mechanisms, leading to cell-cycle arrest and apoptosis, or to DNA repair. Germline 
mutations of B RCA 1 and B RCA2 genes account for only 1 5 -20% of breast cancer 
that clusters in families and less than 5% of breast cancer overall .  
Sporadic brea t cancers are characterize by abnormalities that have been 
identified in several genes including p53 and overexpression of several genes' 
products including HER-2 and estrogen. 
7.1. Hormones and tyrosine kinase receptors (estrogen and HER-2 
receptors) 
I t  has long been recognized that estrogen is involved in the pathogenesis of 
breast cancer that expresses its receptor. In fact, at diagnosis, about 75% of breast 
cancer patients are positive for estrogen receptor (ER) expression, and the 
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remaining 25% of breast cancer patient are ER negative [46] . Distinct gene 
located on eparate chromo orne (6 and 1 4  respecti e ly) can produce two 
different ER: ERa and ERp. The two receptor have different roles in breast 
de elopment. The e receptor are activated with estrogen binding and undergo 
some modificatIOn like dimerization and phosphorylation [47] . Increased 
ERaJERP ratio in brea t cancer a compared with benign tumors and normal tissues 
uggest that ERa is mainly associated with breast cancer pathogenes is , while ERP 
can protect again t the mitogenic activ ity of estrogens in pre-mal ignant les ions 
[48] . Even though es trogen receptors are con idered as weak prognostic factors , 
they are cons idered a s trong predictive factors for identifying patients benefiting 
from endocrine/targeted therapy [49] . 
Epidermal growth factor receptors (EGFRs) are tyros ine kinase 
transmembrane receptor . EGFR family cons is ts of four members : EGFR 1 
(ErbB I IHER 1 ), EGFR2 (ErbB2IHER2), EGFR3 (ErbB3IHER3), and EGFR4 
(ErbB4IHER4). These receptors share s imilar s tructures cons isting of an 
extrace llular l igand-binding domain, a short hydrophobic transmembrane region, 
and an intra-cytoplasmic tyros ine kinase domain. HER-2 eu oncoge ne is the most 
frequently amplified oncogene in breast cancer [50] . Furthermore , an aggressive 
phe notype of breast cancer with poor prognosis were associated with HER-2 over­
express ion in about 25 to 30% of breast tumors [5 1 ] .  
7.2. Non-hormonal factors (p53) 
The tumor suppressor gene p53 was first identified in 1 979 and located on 
chromosome 1 7  [52] . The p53 prote in acts as a checkpoint for several s timuli that 
cause D A damage and apoptosis such as heat shock, hypoxia, radiation and 
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chemIcal drug . Once activated, it accumulate in the nucleus to lllcrea e the 
expression of mdm2 and p2 1 WAF IICIP I , leadlllg to inhibition of cell proliferation 
through G IIG2 cell-cycle arrest [53-57] . Thl check point control, leads to the 
repair of D damage, or to apopto is if the damage cannot be repaired [58] .  The 
vast majority of mutation seen in p53 are mis ense mutations rather than 
truncations or deletions. While 10 s of the tumor-suppressive functions of this gene 
are well recognized, e pres ion of mutant p53 is often seen at a high Ie el in cancer 
and mutant p53 forms appear to be more stable than the wild-type tumor 
suppres or. 
Mutations of p53 are seen in more than 50% of all cancers. One of the best 
known syndrome i Li-Fraumeni,  in which mutation of p53 predisposes to a broad 
range of cancer , including breast cancer, early in l ife [59] .  The p53 mutations 
occur in 30% of non-familial breast cancer patients [60] . It is considered the most 
frequently mutated gene in human breast cancer [6 1 ] .  
8 .  Diagnosis 
Large scale mammography screenings beside women's awareness of the 
state of their breasts by palpation are the most important factors regarding the early 
detection of breast carcinoma and can result in decrease in mortality [62] .  The 
American cancer society recommends an annual screening mammography for 
women who are more than 40 years old and at 25 years of age- with high risk of 
breast cancer, especially those with BRCA I or BRCA2 mutations [62] . In the cases 
of family history of breast cancer, manunography should be perfonned at a younger 
age in order to ensure the detection of the onset of the carcinoma. Not only does the 
diagnosis need to be rapid, but also it is important that the correct subtype of the 
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breast  cancer be defined. Thi is crucial for the treatment of choice and depends on 
the molecular profi le of the cancer. Other s ignificant factors concerning the 
treatment are the lymph node s tatus and the tumor size [63].  
After the initial u pic ion of cancer based on mammography and/or 
palpation ( uch a dense mass in the radiograph, or a palpable lump), biopsy is 
often extracted from the ite of the fmding. Micro copic examination of the biopsy 
is the only \ ay to confirm breast cancer. If cancer ce l ls are present in the biopsy, 
further measures need to be undertaken, such as personal and family medical 
his tories a wel l  a gene ral s igns of health. 
9. Current therapeutic approache 
Once a patient is diagnosed with breast  cancer and the s tage is determined 
the most appropriate therapy should be determined. Breast cancer therapy consists 
of surgery to remove cancerous tissue , cytotoxic-chemotherapy, hormonal therapy, 
targeted therapy and radiotherapy. 
9.1. Chemotherapy 
Chemotherapy can be referred to as cytotoxic drugs used to kill cancer ce l ls .  
If the breast tumor is large , the lymph nodes are concerned or the tumor is found 
close to the chest wall muscles and also in the case of inflammatory breast cancer 
chemotherapy might be recommended before surgery and sometimes even after the 
surgery. 
Chemotherapy drugs can be class ified into many groups according to how they 
work, the ir chemical structure, and their re lationship to drugs . 
Adjuvant chemotherapy is used to kil l  those hidden cancer ce l ls after surgery. 
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eOadjlH all1 chemotherapy: GIving chemotherapy firs t to shr ink a large cancerou 
tumor making it eas ier to be removed with surgery. 
Several cytotoxic drugs are u ed in combinations to treat breast cancer . 
These include combinations of cyclophosphamide, 5-flurouracil, methotrexate , 
doxorubicin docetaxel  and paclitaxe l .  Examples of combinations include :  CMF, 
which con 1 t of cyclopho phamide,  methotrexate , and 5-flurouracil; F AC which 
cons i t of 5 -flurouracil ,  doxorubicin, and cyclophosphamide . 
Chemotherapeutic drugs are class ified into several groups and named 
depending on their cytotoxic mechanism of action, phys iological behaviour, and 
source of the drug. Class ifications include alkylating agents , anti-metabolites , 
anthracyclines, and microtubule s tabi l izers . 
9. 1 .2. Alkylating agents. 
They prevent the cancer ce l ls from proliferation by directly damaging the 
DNA. These agent can work in all phases of the ce l l  cycle . Alkylating agents are 
used as therapy in many different cancers including leukemia as wel l  as lung, 
ovar ian, and breast cancer . Because these drugs damage the DNA, they can cause 
long-term damage to the bone marrow, and this can lead to acute leukemia, that is 
dose-dependent. 
Cyclophosphamide: IS a potent immunosuppressant agent. This prodrug 
should be oxidized to obtain the active metabolite "phosphoramide mustard" 
which exert its cytotoxic effect via transfer of the alkyl groups to the DNA leading 
to ce l l  death [64] .  
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9. 1 .3. Antim tabolite : 
They inhibit pur ine and pyrimidine ba e productions leading to abnormal 
D and R 
5-Fluorouracil: after it uptake by the cell, 5 -FU is converted into different 
active metabolite , \: hich i incorporated into RN and produce aberrant mRNA 
pecle . a pyr imidine analogue, it also incorporated 
into D A indu ing inhibition of DN ynthe ize and leading to cell cycle arres t 
and apopto i [65,66]. 
9. 1 .4. Anthracycl ine 
Anthracycl ine are anti-tumor antibiotics that were introduced in the 1 960s . 
They exert their cytotoxic action through four major mechanisms including 
inhibition of topoi omera e I I ,  blockage of DNA and RNA synthes is and DNA 
trand sc i  s ion, binding to cellular membranes leading to the alteration of fluidity 
and ion transport and fi nally generation of free radicals through an enzyme­
mediated reductive  process [67] . 
Doxorubicin: FDA appro ed in 1 989. It can be used as adjuvant or neoadjuv ant 
chemotherapy to treat ear ly s tage of breast  cancer as wel l as HER2+ breast cancer 
and metas tatic breast cancer patients [68] . Doxorubicin can be used in several 
combinations such as with 5 -flurouracil or cyclophosphamide. 
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9. 1 .5. Microtubule tabil izing ag nt . Include pacl ita el and docetaxel. 
PacLitaxel (Taxol): i of a plant ongm from Pacific Yew tree (Tax us 
bre ifol ia) found in orth merica [69] . Paclita el tabil ize microtubule and a a 
re ult, interfere " ith the normal breakdown of microtubules during cell 
di i ion. hromosome are thu unable to achieve  a metaphase spindle 
configuration. Thi bl ck progre s ion of mito i , and prolonged activation of the 
mitotic checkpoint trigger apopto i or rever ion to the G-phase of the cell cycle 
without cell di i ion [70] . It i recommended in advanced breast cancer. 
9.2 .  Hormonal/Endocrine Therapy 
For more than a century, endocrine therapies for breast cancer patients have 
been u ed. For brea t cancer treatment mo t endocrine therapies act as anti­
proliferative of e tradiol on oestrogen receptor (ER)-pos itive tumor in three ways ; 
either e tradiol i i nh ibited from binding to ER by anti-es trogens or reduction of 
e tradiol concentrations by ovarian ablation in premenopausal women or by 
inhibition of aromatas e  in postmenopausal women to block es trogen production. 
The fir t targeted breas t cancer therapy wa the anti-es trogen receptor 
Tamoxifen and because three quarters of breast cancer patients express estrogen 
and/or progesterone receptors Tamoxifen is used as a firs t  line therapy for the 
treatment of breas t  cancer. Even though it was found to be useful in treating 
es trogen pos itive breas t  cancer in both early and advanced cases, due to i ts partial 
es trogen agonist effect  i t  had many s ide effects such as the risk of endometrial 
cancer [7 1 72] . 
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Aromatase inhibitors are a class of endocrinelhonnonal therapy. They act by 
inhibiting the cytochrome P-450 dependent e nzyme aromatase , which is 
respons ible for converting adrenal androge n  substrates to estrogen .  It is cons idered 
the only ource of endogenous estrogen in postme nopausal women [73] .  Aromatase 
inhibitors are di ided into two groups : revers ible and irrevers ible inhibitors .  
Reversible inhibitors such a Arimidex will  block the e nzyme for  a limited time .  
The second-l ine therapy af ter failure of Tamoxifen is Fulvestrant (se lective 
oestrogen receptor down-regulator) and also a competitor with es trogen for binding 
to the estrogen receptors [74] .  It is also used for the third-line therapy after f ailure 
of tamoxifen and aromatase [75] .  
9.3. HER-2 Receptor Targeted Therapy 
A lmost 30% of breast cancer patients are presented with Her-2 prote in over­
express ion due to the ampl ification of Her-2 gene [76] . Her-2 overexpress ing breast  
cancer is  known for i ts aggress ive nature and short disease -free periods [50,77,78] . 
Trastuzumab, a recombinant humanized monoclonal antibody targeting Her-2 
receptor, proved i ts efficacy in the treatment of breast cancer. Trastuzumab targe ts 
the e xtrace llular domain of HER-2 receptor leading to blockade of several s ignaling 
pathway such as phosphatidylinos itol 3 -kinase and mitogen-activated prote in 
kinase and consequently to ce l l  cycle arrest and apoptos is [79] . Due to its severe 
cardiotoxicity, the use of tras tuzumab draws a big question towards its safety for 
patients . 
2 2  
1 0. Aims of the Re ea rch 
Bre as t  cancer is one of the most common mal ignancies among women. 
Genomic studie ha e increased our understanding of the breast  cancer disease , and 
in combination with screening programs, it has improved survival outcomes of 
breast cancer patie nts .  Remarkable progress has bee n made in the treatment of 
brea t cancer  0 er the years ,  such as hormonal therapy, which depends on tumor 
sens itivity to endocrine manipulation, as we ll as some targeted the rapies that can be 
used e lective ly in tho e patients most l ikely to benefit. However, despite these 
advances , controvers ies remain, patie nts die ,  and a cure remains elus ive . 
The SMARCAD 1 (SWIISNF-related, Matrix-associated, Actin-dependent 
Regulator of Chromatin, containing DEADIH box 1 )  prote in is the human ortholog 
of yea t Saccharoln) ce cerevisiae Fun30 (Function Unknown Now 30) prote in 
[80,8 1 ] .  The Fun30 prote in is a member of the Snf2 he l icase motif -containing 
prote in families , which are known to act as ATP-depende nt DNA transclocators 
[82,83] .  Previous studies have shown that yeast Fun30 de le tions are res is tant to 
ultraviole t  (UV) radiation [84, 85 ] .  The ove r-express ion of Fun30 has bee n  shown 
to affect chromosome s tability, integrity, and segregation [85J .  Simi larly, Fft2, the 
Saccharomyces pombe homologue of Fun30, was found to play a role in 
maintaining chromosomal s tabi l i ty and for the mainte nance of the chromatin 
structure required for kinetochore assembly [86] . In addition, Fun30 was shown to 
interact genetically w ith Cse4 (the histone variant at centromeres) and ChIP-seq 
data confmned Fun30 binding to centromeres [87] .  
Fun30 has also been found to play a role in the promotion of the ce l l  cycle 
along with origin recognition subunit ORC5.  Double mutants of both Fun30 and 
OCR5 were found to accumulate in the G l and early S phase us ing F ACS analysis 
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[88) . ChIP-seq data shows that Fun30 is also located at Autonomously Repl icating 
equences (ARS) sugge ting a role of Fun30 in repl ication [87) . Fun30 has also 
been shown to be a potential cyelin-dependent kinase (Cdk l )/Cdc28 substrate [89] . 
As for its biological activity it has recently been shown that purified Fun30 
forms a homodimer of around 250 kDa and is able to hydrolyze ATP, bind to DNA, 
mononueleosomes and nueleosomal arrays. Fun30 was also shown to have a 
remodeling acti ity using restriction enzymes accessibility assay. In addition, 
Fun30 was found to be more efficient in exchanging histones dirners than in 
repositioning nucleosomes. These biochemical assays provided the first evidence 
that Fun30 is an ATP-dependent chromatin remodeler [8 1 ] . 
Other studies have also implicated Fun30 in heterochromatin regulation 
[88] ;  [86] and in DNA double strand break (DSB) repair by homologous 
recombination [90 9 1 ] . Fun30 was found to faci litate long-range DNA end 
resection in yeast cel ls and this required the ATPase activi ty of Fun30 and other 
resection proteins such as Sgs l and Exo l .  The authors suggested that the activity of 
Fun30 made the DNA more accessible to DNA repair machinery. 
SMARCAD 1 ,  the human ortholog of Fun30, is a DEADIH box-containing 
helicase, which includes proteins essential for repl ication, repair, and transcription. 
In addition to two DEADIH box and an ATP-binding motifs within SMARCAD l ,  
i t  has a putative nuelear local ization signal and several regions that may mediate 
protein-protein interactions. Expression analysis indicates that SMARCAD 1 
transcripts are ubiquitous, with particularly high levels in endocrine t issue [92] .  The 
gene for SMARCAD I has been mapped to the chromosome 4q22-q23m, a region 
rich in break points and deletion mutants of genes involved in several human 
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tissue leiomyosarcoma, hepatocel lular carcinoma, and 
hematologic mal ignancies [80,92]. It has been recently reported that the binding 
sites of endogenous MAR AD l lKIAA 1 l 22 are frequently found in the vicinity 
of transcriptional start ite [93J .  Moreover, human SMARCAD 1 overexpression 
was observed in E IA-e pressing cell line with increased capacity for gene 
reactivation event by genolllic rearrangements suggesting that human 
SMARCAD 1 may play a role in genetic instabil ity development [92 ] .  SMARCAD 1 
has also been hown to work at replication origin si tes in order to facil i tate 
deacetylation of newly assembled histones [94] . Interestingly, a recent paper 
suggested that SMARCAD 1 ju t l ike Fun30, is involved in DNA end resection and 
was recruited to DNA damaged sites were IDA.X is phosphorylated. Silencing the 
SMARCAD 1 gene affected the recruitment of Replication Protein A (RP A) 
indicating reduced formation of s ingle-stranded DNA as in yeast cells [90] . These 
data together suggest an evolutionarily conserved role for the Fun30 and 
SMARCAD 1 chromatin remodelers. 
Dr. Attoub Laboratory have previously shown that the breast cancer cells 
estrogen receptors (ER)-negative MDA-MB-23 1 and MDA-MB-23 1 - 1 833 as well 
as estrogen receptors (ER)-positive cells MCF-7 and T47D expressed a high level 
of SMARCAD I protein in comparison with the human breast epithelial cells 
NHME. 
My master's p roj ect aims to investigate the impact of specific silencing 
of SMA RCAD I on human b reast cancer cell proliferation, colony growth in 
soft agar, m orphology, migration and invasion using human b reast cancer 






2 . 1  Cell cu l ture and reagent 
Human brea t cancer cells MDA-MB-23 1 ,  MDA-MB-23 1 - 1 833 ,  MCF-7 
and T47D were maintained in DMEM medium supplemented with antibiotics 
(penici l l in 50U/ml; streptomycin 50�glml) ( Invitrogen, Cergy Pontoise, France) 
and 1 0% fetal bovine serum (FBS, Biowest, Nouaille, France) at 37°C. The culture 
medium wa changed every three days and cells were passed once a week when the 
culture reaches 95% confluence. The human breast epithelial cells NHME were 
maintained in MEBMT 1 plus SingleQuots™ of Growth Supplements (Lonza, 
Walkervi lle M D, USA). In all experiments, cell viability was higher than 99% 
using trypan blue dye exclusion. Pacl itaxel was purchased from Sigma-Aldrich 
(S igma-Aldrich, Saint-Quentin Fallavier, France). Frondoside A of 99.9% purity 
was purified from Cucumaria frondosa, harvested near Stonington, Maine and 
checked by NMR as previously described [95,96] . SMARTvector 2.0 Lentiviral 
shRNA particles (Dharmacon Thermo Scientific, US) can directly bind to cells and 
deliver their genetically engineered RNA genome to the cytoplasm. The 
SMARTvector 2 .0 includes a turboGFP reporter gene to faci li tate assessment and 
optimization of transduction efficiencies. The SMARTvector 2 .0  also contained a 
puromycin resistance gene for selection and isolation of c lonal populations when 
generating stable cell l ines. 
2.2 Establishment of Stable SMARCAD I silencing in b reast cancer cells 
MDA-MB-23 1 cells were seeded at a density of 20,000 cells / well into 96-
well plates, in  the presence of the serum and allowed to attach for 24h. Cells were 
transfected with SMARTvector 2 .0 Lentiviral shRNA particles targeting 
SMARCAD I or SMARTvector 2 .0 Non-Targeting control part ic les (Dharmacon 
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Thermo Scientific, US). Selection of cells stably expressing SMARCAD l -shRNA 
and the Control-shRNA started 72 h post-transfection following the manufacturer's 
in truction (Dharmacon Thermo cientific, US).  Briefly, growth medium was 
a pirated from the cells and replaced with fresh selection medium containing 1 0  
)lg/mL o f  puromycin. Puromycin-containing medium was replaced every 2-3days 
with fre hly prepared selection medium, and selection of stable cells expressing 
SMARCAD l -shRNA or Control-shRNA was completed in approximately 4 weeks 
from the beginning of selection. Multiple clones and pools of clones were 
expanded harve ted, and prepared for western blot analyses of SMARCAD 1 
e pression. 
2.3 Western blot ana lysis of SMARCAD I protein expression 
Total cellular proteins from stably trans fee ted cells with SMARCAD 1 -
shRNAs and control-shRNA were isolated using RlPA buffer (25Mm Tris .HCI pH 
7 .6 1 %  nonidet PAO, 1 %  sodium deoxycholate, 0. 1 %  SDS, 0 .5% protease 
inhibitors cocktail (S igma, Steinheim, Germany), 1 % phenylmethylsulfonyl 
fluoride, and 1 % phosphatase inhibitors cocktai l  (Themlo Scientific, Rockford, 
USA). The whole cell lysate was recovered by centrifugation at 1 4 ,000 rpm for 20 
minutes at 4°C to remove insoluble material and 30-50 )lg of proteins were 
separated by sodium dodecyl sulfate (SDS) polyacrylamide gel for SMARCAD 1 
expression. After e lectrophoresis, proteins were transferred on a nitro-cellulose 
membrane, blocked with 5% non-fat milk and probed with SMARCAD I (Abeam, 
Bristol ,  UK, 1 : 500) and p-actin (Santa Cruz, Cal ifornia, USA, 1 :  1 000) antibodies 
overnight at 4°C. The blot was washed, exposed to secondary antibodies and 
visualized using the ECL system (Perkin, Waltham, MA, US).  
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2.4 Cell proliferation a ay 
Stable MDA-MB-23 1 cells transfected with SMARCAD l -shRNAs 
(SMARC D l - hR A l  & SMARCAD l -shRNA3) or control sequences (Control­
shRNA) were plated at the density of 50,000 cells into six-well tissue culture 
dishes supplemented with 1 0% FBS. Cancer cells were trypsinized, collected in 1 
ml of  medium and counted at an appropriate dilution every day for five 
consecuti e days. 
2 .5 Soft-agar colony formation assay 
A layer of agar containing I ml of 2 .4% low melting temperature agar (Bio­
Rad) di solved in distilled water was poured into wells of a 6-well cell culture dish 
and allowed to set at 4°C for 5 minutes then incubated at 37°C for 30 min. A 
second layer (2 .9 ml) containing 0.3% of low melting agar dissolved in  growth 
media containing stably transfected cells with SMARCAD I -shRNAs or with 
control-shRNA (20x 1 03 cells / ml) was placed on top of the [lrst layer and al lowed 
to set at 4°C for 5 minutes. After 30 minutes to I -hour incubation in the humidified 
incubator at 37°C, growth medium (2 ml) was added on top of the second layer 
and the cells were incubated in a humidified incubator at 37°C for 3 weeks. 
Medium was changed twice a week. At the end of the experiment, colonies were 
stained for 1 hour with 2% Giemsa stain, and incubated with PBS overnight to 
remove excess stain. The colonies were photographed and scored. 
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2.6 Cel lu lar  Morpholog 
Cel ls  were seeded on four-chamber culture sl ides at a density of 25 000 
cells/chamber. After 48 h, chambers were removed· cells were washed with PBS, 
fixed in 4% paraformaldehyde for ten minutes at room temperature, washed with 
PBS and perrneabilised with 0 . 1 % Triton X- I OO in PBS for 1 0  min. Then, the actin 
cyto keleton was tained with rhodamine phalloidin ( Invitrogen Molecular Probes, 
Oregon, US) and the nuclei were stained with 4 ' ,  6-diamine-2-phenylindole 
dihydrochloride (DAPI) ( Invi trogen Molecular Probes, Oregon, USA). The cells 
were then photographed using an Olympus fluorescence microscope (Olympus 
IX7 1 ,  Japan) for the analysis of theirs morphology. 
2.7 Wou n d  heal ing motil ity assay 
MDA-MB-23 1 cells stably transfected with SMARCAD I-shRNAs or 
control-shRNA were grown in  six-well tissue culture dishes unti l confluence. 
Cultures were incubated for 1 0  min with Moscona buffer. A scrape was made 
through the confluent monolayer with a plastic pipette tip of l rum diameter. 
Afterwards, the dishes were washed twice and incubated at 37°C in fresh DMEM 
containing 1 0% fetal bovine. At the bottom side of each dish, two arbitrary places 
were marked where the w idth of the wound was measured with the inverted 
microscope (objective x4). Motil ity was expressed as the mean ± SEM of the 
difference between the measurements at time zero and the 6 and 24h time period. 
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2.8 M atrigel inva ion a a 
The invasiveness of the breast cancer cells MDA-MB-23 1 stably transfected 
with SMARCAD l -shRNAs or control- hRNA was tested using BD Matrigel 
lnva ion Chamber (8-).lm pore size; BD Biosciences Le Pont de Claix, France) 
according to manufacturer's protocol .  Briefly, Cells ( 1  x 1 05 cells in 0 .5  mL of 
media) were seeded into the upper chambers of the system, the bottom wells in the 
system were fil led with DMEM supplemented with 1 0% fetal bovine serum as a 
cherno-attractant and then incubated at 37°C for 24h. Non-penetrating cells were 
remo ed from the upper surface of the filter with a cotton swab. Cells that have 
migrated through the Matrigel were fixed with 4% formaldehyde, stained with 
DAPI and counted in 25 random fields under a microscope. The assay was carried 
out in duplicate and repeated three times for quantitative analysis. 
2.9 The Oris™ Collagen I Cell I nvasion Assay 
This experiment was used to investigate the impact of SMARCAD 1 
si lencing on MDA-MB-23 1 cell invasion in vitro within a 3 -dimensional 
extracel lular matrix comprised of collagen type I from rat tail CAMS 
Biotechnology, Abingdon, UK). Cells were seeded at 1 00,000 cells / well and 
allowed to attach overnight onto coated plates. Once the cells formed a confluent 
monolayer, the s i l icone stoppers were removed and the cells were incubated for 48 
h invasion. Cells  were then labeled with Calcein AM ( Invitrogen) and images were 
acquired, in the absence of the mask, by use of Olympus fluorescence microscope. 
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2. 1 0  Cel lu lar  viabil ity 
MDA-MB-23 1 -Control-shRNA, MDA-MB-23 1 -Smarcad l -shRNA l and 
MDA-MB-23 1 -Smarcad I -shRNA3 cells were seeded in 96-well plates at a density 
of 5 ,000 cells / well .  After 24h, cells were treated for 24h with increasing 
concentration of frondoside A (0.0 1 -5�M) or pac1itaxel ( l -64nM) in triplicate . 
Control cultures were treated with 0. 1 % DMSO. The effect of the drugs on cell 
viabi l i ty was detennined using a CellTiter-Glo luminescent cell viabi l i ty assay 
(promega Corporation Madison, USA), based on quantification of A TP, which 
signals the presence of metabolically active cells. Luminescent signal was 
measured using GLOMAX Luminometer system. Data were presented as 
proportional viability (%) by comparing the treated group with the untreated cells, 
the viabi li ty of which was assumed to be 1 00%. 
2. 1 1  Statistical Analysis: In the above experiments, results were expressed as 
mean ± S.E .M.  The difference between experimental and control values were 
assessed by ANOVA fol lowed by Dunnett ' s  post-hoc multiple comparison test. 
P<0.05 was taken to indicate a sign ificant difference. 
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Chapter 3 
Results 
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3. 1 H u man Breast Cancer Cell Line 0 er-express SMARCAD l :  The 
expression of the SMARCAD 1 was initially investigated in the human breast 
epithelial cells NHME in comparison with several human breast cancer cell l ines 
including ER-negative MDA-MB-23 1 and MDA-MB-23 1 - 1 833  and ER-positive 
MCF-7 and T470. Western blot analysis of crude protein Iysates ( 1 00 )lg) prepared 
from these cell was performed, using the mouse polyclonal antibody directed 
against SMARCAO l .  We observe in Fig. 1 that all the cells exhibit mainly an 
immunoreactive band with a molecular weight of 1 1 7 KD, corresponding to the 
e pected size of SMARCAD l .  Together with this band, an addit ional minor band 
of 90KD was also detected in lysates from all the cells (Fig 1 ). 
3.2 SMARCAD I si lencing i n  b reast cancer cells MDA-MB-23 1 :  Cells were 
stably transfected with two different designs of SMARTvector 2 .0 Lentiviral 
shRNA particles targeting SMARCAD 1 .  Control cells were transfected with 
SMARTvector 2 .0 Non-Targeting control particles. The positive clones ( 1 0  to 1 2  
from each design) were selected under puromycin (Fig 2 A) and analyzed using 
western blot to confll1n specific SMARCAD 1 si lencing. The two different design 
of shRNA targeting SMARCAD 1 induced 99% decreased in  the SMARCAD I 
protein level (SMARCAD l -shRNA l ,  and SMARCAD 1 -shRNA3). The selectivity 
of this si lencing was confirmed by the fact that no impact on SMARCAD 1 protein 
was observed in the cells transfected with shRNA control particles (control­
shRNA) (Fig 2B) .  The selected c lones were GFP positive (Fig 3). 
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Figu re 1 :  Western blots analysis of SMARCADI protei n expression III 
human breast cancer cel l  l ines M DA-MB-23 1 M DA-MB-23 1 - 1 833  MCF-7 and 
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Figure 2 :  Western blots ana lysis of S MA RCADI protein expression in:  A & 
B) stably transfected M DA-MB-23 1 -Control-shRNA (Clone 4), M DA-MB-23 1 -
SMARCA D l -shRNA l (Clone 3 ), and M DA-MB-23 1 -SMARCAD l -shRNA3 
(Clone 3) cel ls .  
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MDA-MB 231  transfected clones: 
Control-sh RNA Smarcad1 -sh RNA 1 Smarcad 1 -shRNA3 
Figu re 3 :  I m munofluorescence analysis of green fluorescence protein 
expression : the three selected clones from the control and the SMARCAD I 
si lenced cel ls  were photographed for their GFP expression. 
3.3 SMAR CADI silenci ng  decreased M DA-MB-23 1 cell proliferation and 
colonies growth in  soft agar: To test the ability of SMARCAD 1 to interfere with 
cancer cell proliferation, Control-shRNA cel ls  and their SMARCAD I silenced 
counterparts SMARCAD l -shRNA l and SMARCAD l -shRNA3 cells were 
compared for their growth rates. As shown in Fig. 4A, SMARCAD 1 silenced cel ls  
exhibit slower proliferation rates, as shown at days 3 to 5 in culture. At day 5 ,  the 
inhibition was 55 and 35% respectively for SMARCAD I -shRNA 1 and 
SMARCAD l -shRNA3 cel l s. Similarly, SMARCAD I silencing strongly inhibited 
the ability of M DA-MB-23 1 cel l s  to form colonies in soft-agar (Figure 4B &C). 
This interesting data prompted us to investigate the impact of SMARCAD 1 
silencing on the migration and invasion of M DA-MB-23 1 human breast cancer 
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Figu re 4 :  I mpact of SMARCADl silencing on the proliferation and colon ies 
growth of M DA-MB-23 1 breast cancer cells. A) Control and SMARCAD I 
si lenced cel ls  were seeded into six-well tissue culture dishes (50,000 cells /dish) 
and counted daily for 5 days. Data are means ± SEM of 3 independent 
experiments. B) Inhibition of anchorage-independent colonies growth by stable 
silencing of SMARCAD I in M DA-MB-23 1 cells .  20x I 03 of M DA-MB-23 1 -
Control-shRNA, M DA-MB-23 l -SMARCAD l -shRNA l ,  and M DA-MB-23 1 -
SMARCAD l -shRNA3 cel ls  were plated in 0 .3% soft agar. Three weeks later, 
colonies were stained with Giemsa and scored. Statistical differences obtained at 
* P<0.05,  * * P  < 0.0 1 ,  and * * * p  < 0.00 1 . C) Pictures of the colonies formed in 
soft agar were photographed (top panel), and representative single colonies were 
enlarged 40 times (bottom panel) .  
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3.4 M ReA D !  i lencing impairs breast cancer ceU migration and invasio n :  
Breast cancer patients are a t  high risk o f  recurrence i n  the form of metastatic 
disease. Meta tasis starts with the acquisition of a scattered phenotype and cell 
migration in the primary tumor, leading to local tissue invasion and entry into 
lymph or blood e sel . First, the actin cyto keleton of these cancer cells was 
stained with rhodamine phalloidin and theirs nucleus was stained with DAPI for the 
analysis of their morphology. Contrast and fluorescent microscope analysis shows 
that SMARCAD l -shRNA l and SMARCAD 1 -shRNA3 cells have stronger cel l-cell 
adhesion in comparison with Control-shRNA cells (Fig. SA & B). Secondly, we 
examined the effect of S MARCAD I silencing on cel lular migration of MDA-MB-
23 1 cells .  Using wound-healing experiments perfom1ed on sub-confluent cell 
cultures, we show that SMARCAD I silencing inhibited by 67.7 and 50 .8% the 
migration of the SMARCAD l -shRNA l and SMARCAD l -shRNA3 cells 
respectively at the 6h short incubation time considered ( Fig. 6A & B) indicating 
that the inhib ition of cellular migration is not due to the inhibition of cell 
prol iferation. Control-shRNA cells were able to achieve a complete wound healing 
within 24h, while SMARCAD I-shRNA 1 and SMARCAD I -shRNA3 cells were 
unable to fully colonize the wounds at this time period (Fig. 6A & B). 
F inally, we examined the impact of SMARCAD 1 silencing on the 
spontaneously invasive MDA-MB-23 1 cells. As shown in Figure 7A & B, 
selective and stable s i lencing of S MARCAD 1 strongly reversed cellular 
invasiveness of M DA-MB-23 1 cells in matrigel matrix as well as in Oris invasion 
assay (Figure 7 A & B). All together, these results strongly suggest that 
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Figure 5: SMAR CA D I  silencing impairs M DA-M B-23 1 breast cancer cell 
migration and invasion : Morphological changes observed in the SMARCAD 1 
si lenced M DA-MB-23 1 cel ls  were photographed using an inverted microscope 
(A). The actin cytoskeleton was then analyzed wlder a fluorescence microscope 
at three different magnifications after staining with the rhodamine phal loidin 
solution (B). 
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Figure 6 :  SMARCAD I  silencing impairs MDA-M B-23 1 breast cancer cell 
migration and invasio n :  Wounds were introduced in control and SMARCAD I 
silenced confluent mono-layers cultured in the presence of serum. The mean 
distance that cel ls  travel led from the edge of the scraped area for 6 and 24h at 
3 7°C was measured in a bl inded fashion, using an inverted microscope. Data are 
means ± SEM of four independent experiments (A & B). 
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Figure 7 :  S MARCAD I  si lencing impairs MDA-MB-23 1 breast cancer cel l 
migration and invasio n :  M DA-MB-23 1 -Control-shRNA, M DA-MB-23 1 -
SMARCAD I -sbRNA l , and M DA-MB-23 l -SMARCA D l -shRNA3 cel ls  were 
incubated for 24h in the presence of serum. Cells that invaded into Matrigel were 
scored as described in Materials and Methods (A).  Cel ls  were incubated for 48h 
onto an Oris col lagen type I cell invasion assay plate. Cell invasion images were 
acquired by fluorescence microscope ( B) .  All experiments were repeated at least 
three times. * Significantly different at P < 0.05,  * *Significantly different at P < 
0 .0 1 ,  * * *Significantly different at P < 0 .00 1 .  
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3.5 I mpact of M A RC D l  i lencing o n  the anti-ca ncer effect o f  paclitaxel and 
Frondo ide A in vitro: The effect of paclitaxel ( I -64oM) on the viability of the 
Control-shRNA, MARCAD I - hRNA I ,  and SMARCAD 1 -shRNA3 breast cancer 
cells was detennined after 48h incubation (Fig. 8A). No significant enhancement of 
the inhibition of cell iabi lity wa observed following treatment with paclitaxel in 
the SMARCAD I i lenced cells (Fig. 8A). Interestingly, high concentrations of 
Frondo ide A (2 .5 -5�), enhances the inhibition of cellular viabi l ity in the 
SMARCAD l -shRNA l cells as shown in Fig. 8B .  This means that silencing of 
SMARCAD 1 my increases the sensitivity of the breast cancer cells MDA-MB-23 1 
to Frondoside A. However, the SMARCAD l -shRNA3 cells, does not enhance the 
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Figure 8 :  SMARCAD I si lencing enhances the inhibition of cel lular viabil i ty 
i n duced by Frondoside A but  not  by p ac litaxel. Control and SMARCAD 1 
silenced M DA-MB-23 1 cells were treated with vehicle (0. 1 % DMSO) and the 
indicated concentrations of pac1itaxel (A) or Frondoside A (B) for 48h. Viable 
cells were assayed as described in Materials and Methods. All experiments were 
repeated at least three times. *Significantly different at P < 0.05, * *Significantly 





Breast cancer is the most corrunon cancer among woman, and it 1S 
responsible for 1 .3 80 .000 cases and 450.000 deaths each year worldwide [97] . 
Invasion leading to metastasis represents the most devastating attribute of cancer. 
Genes a sociated with in as ion and metastatic virulence provides an aggressive 
edge in survival and prol iferation during colonization of the metastatic site. Breast 
cancer patients are at high risk of recurrence in the fOlm of metastatic disease. 
The SMARCAD I (SWIfSNF-related, Matrix-associated, Actin-dependent 
Regulator of Chromatin, containing DEADIH box 1 )  protein is the human homolog 
of yeast Fun30 (Function Unknown Now 30) proteins. These proteins are members 
of the Snf2 helicase motif-containing protein famil ies, and are known to act as 
ATP-dependent DNA transelocators. Previous studies have shown that yeast Fun30 
deletions are resistant to ultraviolet (UV) radiation. The over-expression of Fun30 
has been shown to affect chromosome stabil ity, integrity, and segregation. Fun30 
has also been shown to be a potential cyel in-dependent kinase (Cdk l )/Cdc28 
substrate. The SMARCAD I is a DEAD/H box-containing helicase, which ineludes 
proteins essential for repl ication, repair, and transcription. Expression analysis 
indicates that SMARCAD I transcripts are ubiquitous, with particularly high levels 
in endocrine t issue . The gene for SMARCAD 1 has been mapped to the 
chromosome 4q22-q23m, a region rich in break points and deletion mutants of 
genes involved in several human diseases, notably soft t issue leiomyosarcoma, 
hepatocellular carcinoma, and hematologic malignancies. Our laboratory have 
previously shown that the breast cancer cells ER-negative MDA-MB-23 1 and 
MDA-MB-23 1 - 1 833 as well as ER-positive MCF-7 and T47 D  expressed a h igh 
level of SMARCAD l in comparison with the normal breast epithel ial cells NHME. 
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In this master research project, we investigated the impact of specific 
silencing of  SMARCAD 1 on human breast cancer cell proliferation growth on soft 
agar, morphology migration and invasion using human breast cancer cells estrogen 
receptors (ER)-negati e MDA-MB-23 I .  In this respect, the M DA-MB-23 1 cells 
were stably transfected with two different design of SMARTvector 2.0 Lentiviral 
shRNA partic les targeting SMARCAD 1 .  Control cells were transfected with 
SMARTvector 2.0 on-Targeting control palticles. The positive clones ( 1 0  to 1 2  
from each design) were selected under puromycin and the GFP positive clones 
were analyzed using western-blot to confirm specific SMARCAD I si lencing. The 
two different design of siRNA targeting SMARCAD I induced 99% decreased in 
the SMARCAD I protein level (SMARCAD l -shRNA l and SMARCAD l ­
shRNA3) .  The selectivity of this s ilencing was confmned by the fact that no impact 
on SMARCAD 1 protein was observed in the cells transfected with shRNA control 
particles (control-shRNA). We demonstrated for the first time that silencing of 
SMARCAD 1 resulted in a significant inhibit ion of cel lular proliferation and 
colonie formation in soft agar as wel1 as cellular migration and invasion. All  
together, these results strongly suggest that SMARCAD I may play an important 
role in breast cancer growth and metastasis .  
I t  has been previously reported that deletion of Fun30, was associated with a 
delay in  the cel l  cycle leading to an inhibition in the proliferation (AI Marzouqi et 
ai, unpublished data). Similarly, we report in this study that si lencing of 
SMARCAD 1 ,  the mammalian homologue of Fun30, is also associated with an 
inhibition of cell  proliferation leading to a decrease in the colony growth. 
Metastasis is the major cause of morbidity and mortal ity in breast cancer 
patients that causes nearly half a mil l ion deaths each year worldwide [98] . This 
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multi -step process in olves increased motil ity of the tumor cells, invasion of nearby 
tissue and intravasation into blood and lymphatic circulation. Finally breast 
carcinomas colonize distant organs, mainly the brain liver, bone and lungs. Patients 
with metastatic cancer have a low chance of achieving long-term survival after 
chemotherapy [99) . Metastasis can occur at later stages during therapy or several 
years following treatment. 
Therefore, to wlderstand the molecular mechanisms of cancer metastasis, it 
IS necessary to identify the genes whose alterations accumulate during cancer 
progre ion as well as the genes whose expression is responsible for the acquisition 
of metastatic potential in cancer cells which can be classified into three groups: 
metastasis initiation, metastasis progression and metastasis virulence genes [ 1 00). 
Initiation of metastatic genes involves promoting cell motil ity, invasion, epithelial­
mesenchymal transition (EMT) , extracellular matrix degradation, bone marrow 
progenitor mobi l ization and angiogenesis [ 1 0 1 ) .  In this study, we observed from the 
morphology of SMARCAD I si lenced MDA-MB-23 1 ,  that the silencing of 
SMARCAD I is associated with stronger cell-cel l  adherence leading to the 
inhibition of cel lular migration and invasion. 
These results are in total agreement with recent work demonstrating that the 
silencing of BRG 1 ,  a core component of the SWI/SNF chromatin-remodeling 
complex, l ike the silencing of SMARCAD 1 markedly inhibits breast cancer 
cel l prol iferation and reduces MMP-2, thereby inhibiting the ability of cells to 
migrate and to invade [ 1 02) .  However, both studies are in contrast with previous 
publications reporting that chromosomal instabi lity is associated with higher 
expression of genes implicated in Epithel ial-Mesenchymal Transition, cancer 
invasiveness, and metastasis and with lower expression of genes involved in cel l 
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cycle checkpoints, D A repair, and chromatin maintenance [ 1 03] and that the 
alterations in chromatin play an important role in breast cancer progression and 
meta tasis [ 1 04] . 
Frondoside A i a triterpenoid glyco ide isolated from the Atlantic 
cucumber Cucumaria jrolldosa [ 1 05 ] .  Low concentrations of Frondoside A inhibit 
the growth and induced apoptosis of human pancreatic, leukemia, lung and breast 
cancer cells via ca pase activation [ 1 06- 1 09]. It has also been demonstrated that 
Frondoside A has an anti-invasive and anti-metastatic effect on human breast and 
lung cancer cells [ 1 08, 1 09] . Frondoside A enhances breast cancer cell death 
induced by the chemotherapeutic agent Pac1itaxel [ 1 09] .  Pac1 itaxel has considerable 
cl inical acti ity against a variety of malignancies including breast cancer. 
Pacl itaxel, known to stabi lize microtubules, inhibit cell division and induces death 
of breast cancer cells [ 1 1 0] .  
I n  the current study, w e  investigated the possible contribution of 
SMARCAD I silencing to the anti-cancer effect of Paclitaxel and Frondoside A in 
vitro. No additional inhibition of cel l viabi li ty was observed after treatment with 
Pac1itaxel in the s i lenced SMARCAD 1 cells in comparison with control-shRNA 
cells .  However, the inhibition of cellular viability with high concentrations of 
Frondoside A was enhanced in the SMARCAD l -shRNA l cells. This may suggest 
that we can increase the sensitivity of the breast cancer cell l ines to Frondoside A 
by si lencing SMARCAD I .  This result is consistent with previous study showing 
that the loss of SMARCAD 1 impairs end resection and recombinational DNA 
repair, and renders cells hypersensitive to DNA damage resulting from 
camptothecin or poly(ADP-ribose) polymerase inhibitor treatments [90] . 
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In conclusion, we have identified that specific si lencing of SMARCAD 1 
decrea e cel lular proli feration, colony growth, migration and invasion of the human 
brea t cancer cells estrogen receptors (ER)-negative MDA-MB-23 1 .  This study is 
the first demon tration of the role of SMARCAD 1 in human breast cancer 
progre s ion. Increa ed SMARCAD 1 expression may facil itate tumor progression 
by enhancing cell growth, migration and invasion. Our results imply that 
SMAR AD 1 may serve as a prognostic marker as well as a potential therapeutic 
target for breast cancer. 
Perspectives of the p resent stu dy 
1 .  I mpact of SMARCAD silencing on  trans-endothelial migration of MDA­
M B-23 1 ceUs t h rough H UVEC cells:  Briefly, transwell filters wil l  be coated with 
col lagen type I and allowed to dry for I hour. HUVECs 1 50,000/well will then be 
seeded onto the rehydrated membrane and al lowed to grow for 24 hours until a 
confluent monolayer is fonned. Then, l x l Os of the breast cancer cells MDA-MB-
23 1 stably tran fected with SMARCAD l -shRNAs or control-shRNA wil l  then be 
loaded on top and incubated overnight in 0. 1 % serum, the bottom wells in the 
system wil l  be fil led with DMEM supplemented with 1 0% fetal bovine serum as a 
cherno-attractant. on-penetrating cells in the upper chamber wi l l  removed with a 
cotton swab, whereas MDA-MB-23 1 in the bottom wil l  be fixed with 4% 
formaldehyde, stained with DAPI and quantified for GPF expression in 25 random 
fields under a microscope [ 1 1 1 ] .  
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2 .  I mpact of SMA RC A D  ilencing on the expression of the metastatic 
upp re or gene E-cad heri n :  It is well known that disruption of cell-cell adhesion 
during cancer progression is the initial stage required for the acquisition of invasive 
properties and characterized by a decreased expression of E-cadherin. E-cadherin, a 
calcium-dependent, cell adhe ion molecule, is considered as a tumor suppressor in 
breast cancer [ 1 1 2] .  Decrease of E-cadherin expression is a critical and necessary 
event required in the disruption of cell-cell adhesion and thus for the acquisition of 
invasi e phenotype of vruious tumors including breast cancer. In fact, 
downregulation or loss of E-cadherin during cancer progression is associated with 
aggressive behavior of the tumor and poor prognosis [ 1 1 3] .  Conversely, expression 
of E-cadherin led to a reduced progression and invasion of breast cancer cells 
[ 1 1 4] .  In this context we will investigate the impact of SMARCAD silencing on 
the expression of the metastatic suppressor gene E-cadherin .  
3. I mpact of SMARCAD I  si lencing on cellular aggregation : We showed in this 
thesis that SMARCAD l -shRNA l and SMARCAD l -shRNA3 cells have stronger 
cell-cell adhesion compared to control-shRNA cells .  Therefore we would l ike to 
investigate the impact of SMARCAD I s ilencing on the MDA-MB-23 1 adhesive 
properties using two assays. 
A. Slow aggregation assay: s ingle-cel l  suspensions wi l l  be seeded onto a semi­
solid agar medium. After 24 h, aggregate formation wi l l  be evaluated subjectively 
by phase-contrast microscopy. 
B. Fast aggregation assay: single-cell suspensions wil l  be prepared using an E­
cadherin saving procedure [ 1 1 5] .  Cells wi l l  be incubated in  an isotonic buffer 
containing 1 .25mM Ca2+ under gyratory shaking for 30 min at 37C. Particle 
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diameters wil l  be mea ured in a particle size counter (LS 200; Beckman Coulter, 
Miami, Fl US) at the start (to) and after 30-min incubation (t30), and plotted 
against percentage volume distribution. 
4. Abil ity of SMARCAD I to transactivate different su bsets of target genes to 
orchestrate cell p rol iferation and colony growth or migration and invasion : 
This objective wil l  be investigated in MDA-MB-23 1 cells transfected with 
SMARCAD I -shRNAs (SMARCAD 1 -shRNA 1 & 3) or control sequences (Control­
shRNA) using real-time PCR Array of Human Signalling in 384-well Plate 
containing 380 human genes associated with breast cancer, transcription, 
survivaVapoptosis, cell cycle, Epithelial Mesenchymal transition, invasion, cell-cell 
adhesion, cell-matrix adhesion, metastasis, DNA replication/repair, and nucleotide 
synthesis and 4 assays of endogenous control gene (GAPDH) in a customize array 
(Applied Biosystems, US).  Genes that are more than two fold up or down regulated 
wil l  be analysed using RT-PCR or Western-blot. 
5. I mpact of SMARCA D l  si lencing on  tumor growth a n d  metastasis in nude 
mice 
A. Tumor growth assay in vivo: S ix-week-old athymic NMRI nude mice 
(nulnu, Charles River, Suizfeld, Germany) will be maintained under specified 
pathogen-free conditions. Human breast cancer cells MDA-MB-23 1 stably 
transfected with SMARCAD I -shRNAs (SMARCAD I -shRNA l ,  and 
SMARCAD 1 -shRNA3) or control sequences (Control-shRNA) (5 x 1 06 cells 
mixed v/v with matrigel) will be injected subcutaneously into the lateral flank of 
the mice. Throughout this study, nude mice will be housed in filtered-air laminar 
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flow cabinets and manipulated following aseptic conditions. Procedures involving 
animals and their care will  be conducted in conformity with Institutional guidelines 
that are in compliance with col lege of Medicine & Health Sciences national and 
international laws and pol icies (EEC Council Directive 86/609, OJ L 358,  1 ,  
December 1 2, 1 987;  and IH Guide for Care and Use of Laboratory Animals, Nlli 
Publ ication No. 85-23 1 985) .  Tumor dimensions will be measured with calipers 
e ery week. Tumor volumes (V) were calculated using the formula: V = a x b2 x 
0.4, with "a" being the length and "b" the width of the tumor. The animals wil l  be 
sacrificed six weeks after cells injection and tumors and axil lary lymph nodes wil l  
be exci ed and weighed to determine the impact of SMARCAD 1 silencing on 
tumor growth and lymph node metastasis .  
B. M etastasis assay in vivo: Six-week-old athymic NMRI nude mIce 
(nu/nu, Charles River Suizfeld, Germany) wil l  be maintained under specified 
pathogen-free conditions. Hwnan breast cancer cells M DA-MB-23 1 stably 
transfected with SMARCA D 1 -shRNAs (SMARCAD 1 -shRNA 1 ,  and 
SMARCAD 1 -shRNA3) or control sequences (Control-shRNA) ( 1  x 1 05 cells in 
1 00�.t1 media) wi l l  be injected intravenously into the lateral tail vein of the mice. 
Throughout this study, nude mice will be housed in filtered-air laminar flow 
cabinets and manipulated following aseptic conditions. Procedures involving 
animals and their care wi l l  be conducted in conformity w ith Institu tional guidelines 
that are in compliance with college of Medicine & Health Sciences, national and 
international laws and policies (EEC Council Directive 86/609, OJ L 358,  1 ,  
December 1 2, 1 987;  and NIH Guide for Care and Use of Laboratory Animals, Nlli 
Publication No. 85-23 ,  1 985) .  The animals wil l  be sacrificed three months after 
5 2  
cel ls injection and lungs wil l  be excised and weighed to detennine the impact of 
SMARCAD 1 si lencing on lung metastasis. These cells are stably transfected with a 
vector encoding green fluorescence protein, to allow a rapid and reliable 
quantification of micro-metastases in the lungs. 
6. I m mu n o histochemical expression of SMARCADl in n ormal and breast 
cancer tissues:  We have a total of 58 breast samples of breast carcinomas 
fonnalin-fixed paraffm-embedded retrieved from the Department of Pathology 
archives that wil l  be used after receiving ethical approval from the Al Ain Medical 
District Human Research Ethics Committee. These cases have been previously 
studied and characterized for their ER, PR and HER2 status. We also have 4 1  
tumor-free tissues from same group of patients. Immunostaining o f  SMARCAD I 
wi l l  be carried out on deparaffinized sections using the avidin-biotin-peroxidase 
complex method. After inhibition of endogenous peroxidases with 3% hydrogen 
peroxide, sl ides wi l l  be washed in PBS and incubated with 1 0% BSA at room 
temperature for 60 minutes. SMARCAD I immunoreactivity wil l  be detected using 
a goat polyc1onal antibody directed against the human SMARCAD 1 ( 1 :  50; Santa 
Cruz Biotechnology, Santa Cruz, CA) for 2 hours at room temperature in a 
humidified chamber. SMARCAD I immunohistochemistry specificity wil l  be 
checked by omission of primary antibody. Al l  slides wi l l  be rinsed three times with 
TBS; sections wi l l  be incubated with biotinylated secondary antibody ( 1  : 500; 
Vector Laboratories, Burlingame, CA) for 60 minutes at room temperature. The 
antigen-antibody complex wi l l  be revealed with avidin-biotin-peroxidase complex 
for 60 minutes according to the manufacturer' s  instructions for the Vectastain ABC 
kit (Vector Laboratories). Staining wil l  done for 5 minutes w ith 3,3�­
diarninobenzidine (Sigma-Aldrich, Lyon, France). Al l  sl ides wi l l  be counterstained 
53 
with hematoxyl in. A semi-quantitative estimation of the number of positive cells 
will be done by counting 1 ,000 reactive and nonreactive cells in 1 0  successive 





1 .  Curado MP (20 1 1 )  Breast cancer in the world :  incidence and mortality. Salud 
Publica Mex 5 3 :  372-384. 
2 .  Ahmedin Jema! D PhD l ,  Freddie Bray P, Mel issa M. Center M, Jacques Ferlay 
M (20 1 1 )  Global Cancer Stat istics .  a cancer journal for c l in icians 7 1 .  
3 .  Heather Chappel l  PD, Dagny Dryer,Larry Ell ison,Heather Logan (20 1 1 )  
Canadian Cancer Statistics in Canada. Territorial Cancer Registration, 
Public Health Agency of Canada Cancer: 30 
4. HAAD U (20 1 1 )  Breast Clinical Care Pathways. pp. 
http://w\\.w.haad.aeI11aadltabid17 861Defau I t.aspx . 
5. Baselga J, Norton L (2002) Focus on breast cancer. Cancer Cel l  1 :  3 1 9-322. 
6. J iang X, Castelao JE, Chavez-Uribe E, Fernandez Rodliguez B, Celeiro Munoz 
C, et a1. (20 1 2) Family history and breast cancer hormone receptor status in 
a Spanish cohort. PLoS One 7: e29459. 
7 .  Venna R Bowen RL, Slater SE, Mihaimeed F, Jones JL (20 1 2) Pathological and 
epidemiological factors associated with advanced stage at diagnosis of 
breast cancer. Br Med Bull 1 03 :  1 29- 1 45 .  
8 .  Richie RC, Swanson JO (2003) Breast cancer: a review of the l i terature. J Insur 
Med 3 5 :  85- 1 0 1 .  
9. Ly D, Forman D, Ferlay J,  Brinton LA, Cook MB (20 1 2) An international 
comparison of male and female breast cancer incidence rates. Int J Cancer. 
1 0 . Mitchel l  DG, Snyder B, Coakley F, Reinhold C, Thomas G, et a1. (2006) Early 
invasive cervical cancer: tumor delineation by magnetic resonance imaging, 
computed tomography, and c linical examination, verified by pathologic 
results, in the ACRIN 665 1 1GOG 1 83 Intergroup Study. J Clin Oncol 24 : 
5687-5694. 
1 1 . Onland-Moret NC, Kaaks R, van Noord PA, Rinaldi S, Key T, et a1. (2003) 
Urinary endogenous sex hormone levels and the risk of postmenopausal 
breast cancer. Br J Cancer 88 :  1 394- 1 399. 
1 2 . ( 1 997) Breast cancer and hormone replacement therapy: col laborative 
reanalysis of data from 5 1  epidemiological studies of 52,705 women with 
breast cancer and 1 08,4 1 1 women without breast cancer. Collaborative 
Group on Hormonal Factors in Breast Cancer. Lancet 350 :  1 047- 1 059. 
56 
1 3 . Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, et al . (2000) Menopausal 
estrogen and estrogen-progestin replacement therapy and breast cancer risk. 
JAMA 283 : 485-49 l .  
14 .  ParI FF, Dawling S, Roodi N, Crooke PS (2009) Estrogen metabol ism and 
breast cancer: a risk model . Ann N Y  Acad Sci 1 1 55 :  68-75.  
1 5 .  Rohan T (2007) Epidemiological studies of vitamin D and breast cancer. Nutr 
Rev 65 :  S80-83. 
1 6. Cui Y, Rohan TE (2006) Vitamin D, calcium, and breast cancer risk: a review. 
Cancer Epidemiol Biomarkers Prev 1 5 :  1 427- 1 437 .  
1 7 . Porter GA, Inglis KM, Wood LA,  Veugelers PJ  (2006) Effect of obesity on 
presentation of breast cancer. Ann Surg Oncol 1 3 : 327-332.  
1 8. Key TJ, Appleby PN, Reeves GK, Roddam A Dorgan JF, et a1 . (2003) Body 
mass index semm sex honTIones, and breast cancer risk in postmenopausal 
women. J Natl Cancer Inst 95 :  1 2 1 8- 1 226. 
1 9 . Sellers TA Kushi LH, Potter JD, Kaye SA, Nelson CL, et a1. ( 1 992) Effect of 
family history, body-fat distribution, and reproductive factors on the risk of 
postmenopausal breast cancer. N Engl J Med 326: 1 323 - 1 329. 
20. Stephenson GD, Rose DP (2003) Breast cancer and obesity: an update. Nutr 
Cancer 45 : 1 - 1 6. 
2 l .  Rock CL, Demark-Wahnefried W (2002) Nutrition and survival after the 
diagnosis of breast cancer: a review of the evidence. J C1in Oncol 20: 3302-
33 1 6 . 
22 .  Plant AL Benson DM, Smith LC ( 1 985) Cellular uptake and intracellular 
localization of benzo(a)pyrene by digital fluorescence imaging microscopy. 
J Cell BioI 1 00: 1 295- 1 308. 
23. Messina CR, Kabat GC, Lane DS (2002) Perceptions of risk factors for breast 
cancer and attitudes toward mammography among women who are current, 
ex- and non-smokers. Women Health 36: 65-82.  
24. Terry PD, Mi l ler AB, Jones JG, Rohan TE (2003) Cigarette smoking and the 
risk of invasive epithelial ovarian cancer in a prospective cohort study. Eur J 
Cancer 39 :  1 1 5 7 - 1 1 64. 
25.  John EM, Phipps AI, Knight JA, Milne RL, Dite GS, et a1. (2007) Medical 
radiation exposure and breast cancer risk : findings from the Breast Cancer 
Family Registry. Int J Cancer 1 2 1 :  3 86-394. 
57 
26. Markowitz SD Bertagnoll i  MM (2009) Molecular origin of cancer: Molecular 
ba is of colorectal cancer. N Engl J Med 36 1 :  2449-2460. 
27 .  Martin AM, Blackwood MA, Antin-Ozerkis D, Shih HA Calzone K, et al . 
(200 1 )  Gerrnline mutations in BRCA 1 and BRCA2 in breast-ovarian 
families from a brea t cancer ri k evalua60n clinic. J Cl in Oncol 1 9 : 2247-
2253 .  
28 .  Chen S I er en ES, Friebel T,  Finkelstein D,  Weber BL,  et  al .  (2006) 
Characterization of BRCA 1 and BRCA2 mutations in a large United States 
ample. J Clin Oncol 24: 863-87 1 .  
29. Cao AY, He M, Dr GH, Wu J, Lu JS,  et al .  (20 1 1 )  Influence of a family history 
of breast and/or ovarian cancer on breast cancer outcomes. Exp Ther Med 2 :  
9 1 7-923 .  
30 .  Easton DF, Ford D Bishop DT ( 1 995) Breast and ovarian cancer incidence in 
BRCA I -mutation carriers. Breast Cancer Linkage Consortium. Am J Hum 
Genet 56 :  265-27 l .  
3 1 .  Chang ET, Mi lne RL, Phillips KA, Figueiredo JC, Sangaramoorthy M,  et al . 
(2009) Family history of breast cancer and aU-cause mortal ity after breast 
cancer diagnosis in the Breast Cancer Family Registry. Breast Cancer Res 
Treat 1 1 7 :  1 67 - 1 76. 
32 .  Couch FJ, DeShano M L, Blackwood MA, Calzone K, Stopfer J ,  et al . ( 1 997) 
BRCA I mutations in women attending clinics that evaluate the risk of 
breast cancer. N Engl J Med 336 :  1 409- 1 4 1 5 . 
33 .  Gasco M,  Shami S, Crook T (2002) The p53 pathway in breast cancer. Breast 
Cancer Res 4: 70-76. 
34. Angelopoulou K, Yu H,  Bharaj B, Giai M,  Diamandis EP (2000) p53 gene 
mutation, tumor p53 protein overexpression, and serum p53 autoantibody 
generation in patients with breast cancer. Clin Biochem 3 3 :  53-62 . 
35 .  Vegran F, Rebucci M,  Chevrier S, Cadouot M,  Boidot R, et al .  (20 1 3) Only 
missense mutations affecting the DNA binding domain of p53 influence 
outcomes in patients w ith breast carcinoma. PLoS One 8: e55 1 03 .  
3 6 .  Walerych D,  Napoli  M,  Col lavin L, Del Sal G (20 1 2) The rebel angel :  mutant 
p53 as the driving oncogene in breast cancer. Carcinogenesis 33 :  2007-
20 1 7 . 
58 
37 .  Slamon D, Eierrnann W Robert N Pienkowski T, Martin M, et at .  (20 1 1 )  
Adju ant tra tuzumab in HER2-positive brea t cancer. Engl J Med 365: 
1 273- 1 283 .  
38 .  Ann Ehrlich CLS (2004) Medical Tenninology for Health Professions: Delmar 
Cengage Learning. 
39. Recht A, Rutgers EJ Fentiman IS, Kurtz JM, Mansel RE, et al. ( 1 998) The 
fourth EORTC DCIS Con ensus meeting (Chateau Marquette, Heemskerk, 
The Netherland 23-24 January 1 998)--conference report . Eur J Cancer 34: 
1 664- 1 669. 
40. Minneapolis M (2009) Diagnosis and Management of Ductal Carcinoma in Situ 
(DCIS). Agency for Healthcare Research and Qual ity US Department of 
Health and Human Service: 549. 
4 1 .  Kleer CG, van Golen KL, Merajver SO (2000) Molecular biology of breast 
cancer metastasis. Inflammatory breast cancer: c l inical syndrome and 
molecular determinants. Breast Cancer Res 2 :  423-429. 
42. Martin BJ, van Golen KL (20 1 2) A comparison of cholesterol uptake and 
storage in inflammatory and noninflammatory breast cancer cells. Int J 
Breast Cancer 20 1 2 :  4 1 25 8 l .  
43 . Chang S,  Parker S L  Pham T, Buzdar AU, Hursting SD ( 1 998) Inflammatory 
breast carcinoma incidence and survival : the surveil lance, epidemiology, 
and end results program of the National Cancer Institute, 1 975- 1 992. 
Cancer 82: 2366-2372. 
44. Singletary SE, Allred C,  Ashley P, Bassett LW, Berry 0, et al .  (2002) Revision 
of the American Joint Committee on Cancer staging system for breast 
cancer. J C lin Oncol 20: 3628-3636. 
45.  Kirui JK, Xie Y,  Wolff OW, Jiang H,  Abel PW, et at. (20 1 0) Gbetagamma 
signaling promotes breast cancer cell migration and invasion. J Pharrnacol 
Exp Ther 333 :  393-403 .  
46. Cleator S J ,  Ahamed E,  Coombes RC, Palmieri C (2009) A 2009 update o n  the 
treatment of patients with hormone receptor-positive breast cancer. Clin 
Breast Cancer 9 Suppl 1 :  S6-S 1 7 . 
47. Osborne CK, Schiff R (2005) Estrogen-receptor biology: continuing progress 
and therapeutic implications. J Clin Oncol 23 : 1 6 1 6- 1 622. 
59 
48. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P et al .  (200 1 )  Decreased 
expression of e trogen receptor beta protein in proliferative preinvasive 
mammary tumors. Cancer Res 6 1 :  2537-254 1 .  
49. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, et a1. (2006) 
Estrogen-receptor tatu and outcomes of modem chemotherapy for patients 
with node-positi e breast cancer. Jama 295:  1 658- 1 667. 
50. Siamon DJ Godolphin W, Jones LA, Holt JA, Wong SG, et a1 .  ( 1 989) Studies 
of the HER-2/neu proto-oncogene in human breast and ovarian cancer 
Science 244 707-7 1 2 . 
5 1 .  Cobleigh MA Vogel C L, Tripathy D, Robert NJ, Scholl S, et a! .  ( 1 999) 
Multinational study of the efficacy and safety of humanized anti-HER2 
monoc lonal antibody in women who have HER2-overexpressing metastatic 
breast cancer that has progressed after chemotherapy for metastatic disease. 
J Clin Oncol 1 7 : 2639-2648 . 
52 .  DeLeo AB Jay G, Appella E, Dubois GC Law LW et a1. ( 1 979) Detection of a 
transfonnation-related antigen in chemical ly induced sarcomas and other 
transfonned cells of the mouse. Proc Natl Acad Sc i U S A  76: 2420-2424. 
5 3 .  M ichieli P ,  Chedid M, Lin D, Pierce JR, Mercer WE, et al .  ( 1 994) Induction of 
WAF l IC IP I  by a p53-independent pathway. Cancer Res 54: 339 1 -3395. 
54. Oren M (2003) Decision making by p53 :  l ife, death and cancer. Cell Death 
Differ 1 0: 43 1 -442 . 
55 .  Sionov RV, Haupt Y ( 1 999) The cel lular response to p53 :  the decision between 
l ife and death . Oncogene 1 8 : 6 1 45-6 1 57 .  
56.  Stewart ZA, Pietenpol JA (200 1 )  p53 Signaling and cel l  cycle checkpoints. 
Chern Res Toxicol 1 4 :  243-263 . 
57 .  Vousden KH Lu X (2002) Live or let die: the cell 's response to p53 .  Nat Rev 
Cancer 2: 594-604. 
58 .  Oren M ,  Rotter V ( 1 999) Introduction: p53--the fIrst twenty years. Cell Mol 
Life Sci 5 5 :  9- 1 1 . 
59. Li FP, Fraumeni JF, Jr. ( 1 982) Prospective study of a family cancer syndrome. 
Jama 247: 2692-2694. 
60. Davidoff AM, Humphrey PA, Iglehart JD, Marks JR ( 1 99 1 )  Genetic basis for 
p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A  88 :  
5006-50 1 0 . 
60 
6 1 .  Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in 
ivo veritas. at Rev Cancer 6: 909-923.  
62.  Corcoran T ( 1 999) Treatment of breast cancer. Engl J Med 340: 3 1 9 · author 
reply 320. 
63 . Alejandro Tejerina Bernal, Antonio Tejerina Bernal, Francisco Rabad 'an 
Doreste, Ana De Lara Gonz'alez, Juan Antonio Rosell '0 Llerena, et al. (4 
June 20 1 2) Brea t Imaging: HowWeManage Diagnostic Technology at 
aMultidiscipl inary Breast Center. Journal of Oncology 20 1 2 : 9 .  
64 . Fleming RA ( 1 997) An overview of cyclophosphamide and ifosfamide 
pharmacology. Phannacotherapy 1 7 : 1 46S- 1 54S. 
65. Schmitz JC, Liu J,  Lin X, Chen TM, Yan W, et al .  (200 1 )  Translational 
regulation as a novel mechanism for the development of cel lular drug 
resistance. Cancer Metastasis Rev 20: 33-4 1 .  
66. Balachandran S,  Kim CN, Yeh WC, Mak TW, Bhalla K, et al .  ( 1 998) 
Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis 
through FADD-mediated death signaling. EMBO J 1 7 : 6888-6902. 
67. Kalant H, Grant DM, Mitchell J, editors (2006) Principles of Medical 
Phannacology. 7 ed: Elsevier. 
68. Kovar L, Strohalm J, Chyti l  P, Mrkvan T Kovar M, et al. (2007) The same 
drug but a different mechanism of action: comparison of free doxorubicin 
w ith two different N-(2-hydroxypropyl)methacrylamide copolymer-bound 
doxorubicin conjugates in EL-4 cancer cell l ine. Bioconjug Chern 1 8 : 894-
902. 
69. Jordan MA (2002) Mechanism of action of antitumor drugs that interact with 
microtubules and tubul in .  CUlT Med Chern Anticancer Agents 2: 1 - 1 7 . 
70. Bharadwaj R, Yu H (2004) The spindle checkpoint, aneuploidy, and cancer. 
Oncogene 23 :  20 1 6-2027. 
7 1 .  Henderson IC, Hayes DF, Gelman R ( 1 988) Dose-response in the treatment of 
breast cancer: a critical review. J Clin Oncol 6 :  1 50 1 - 1 5 1 5 . 
72. Vahdat L ,  Antman KH ( 1 995) Dose-intensive therapy in breast cancer. In:  
Antrnan KH, Arrnitage JA, editors. High-dose cancer therapy: 
phannacology, hematopoietins and stem cells. Baltimore: Lippincott 
Wil liams & Wilkins. pp. 802-882.  
61 
73.  obholtz JM, Buzdar A, Pollak M Harwin W, Burton G, et  al .  (2000) 
Ana trozole is uperior to tamoxifen as ftrst l ine therapy for advanced breast 
cancer in po tmenopausal women: results of a north american multicenter 
randomized trial .  Jounral of Clinical Oncology 1 8 : 3758-3767. 
74. Osborne CK, Wake l ing A, Nicholson RI (2004) Fulvestrant: an oestrogen 
receptor antagoni t with a novel mechanism of action. Br J Cancer 90 Suppl 
1 :  S2-6. 
75 .  Society AC (2007) ACS, Cancer Drug Guide: fulvestrant. 
76. Konecny GE, Pegram MD Venkatesan N Finn R, Yang G, et al. (2006) 
Activity of the dual kinase inhibitor lapatinib (GW5720 1 6) against HER-2-
overexpres ing and trastuzumab-treated breast cancer cells. Cancer Res 66: 
1 630- 1 639. 
77. Ross JS  Fletcher JA ( 1 998) The HER-2/neu oncogene in breast cancer: 
prognostic factor, predictive factor, and target for therapy. Stem Cells 1 6 : 
4 1 3-428.  
78.  Slamon DJ, Clark GM, Wong SG, Levin WJ, Ul lrich A, et al .  ( 1 987) Human 
breast cancer: correlation of relapse and survival with ampliftcation of the 
HER-2/neu oncogene. Science 235 :  1 77- 1 82 .  
79. Nahta R, Yu D, Hung MC,  Hortobagyi GN, Esteva FJ (2006) Mechanisms of 
disease: understanding resistance to HER2-targeted therapy in human breast 
cancer. at Clin Pract Oncol 3 :  269-280. 
80. Soininen R, Schoor M,  Henseling U, Tepe C, Kisters-Woike B, et al .  ( 1 992) 
The mouse Enhancer trap locus 1 (Etl- l ) : a novel manunalian gene related 
to Drosophila and yeast transcriptional regulator genes. Mech Dev 39:  1 1 1 -
1 23 .  
8 1 .  Awad S ,  Ryan D ,  Prochasson P ,  Owen-Hughes T ,  Hassan AH (20 1 0) The Snfl 
homolog Fun30 acts as a homodimeric A TP-dependent chromatin­
remodeling enzyme. J Bioi Chern 285 :  9477-9484. 
82. Flaus A,  Martin DM, Barton GJ, Owen-Hughes T (2006) Identiftcation of 
mUltiple distinct Snfl subfami l ies with conserved structural motifs .  Nucleic 
Acids Res 34 : 2887-2905 . 
83 .  Dtirr H, Flaus A, Owen-Hughes T, Hopfner KP (2006) Snfl family ATPases 
and DExx box helicases: differences and unifying concepts from high­
resolution crystal structures. Nucleic Acids Res 34:  4 1 60-4 1 67. 
62 
84. Clark MW, Zhong WW, Keng T, Storms RK, Barton A, et al .  ( 1 992) 
Identification of a Saccharomyces cerevisiae homolog of the SNF2 
transcriptional regulator in the DNA sequence of an 8 .6 kb region in the 
LTE I -CYS I interval on the left ann of chromosome I. Yeast 8: l 33- 1 45 .  
85 .  Balion AB,  Kaback DB ( 1 994) Molecular cloning of  chromosome I DNA from 
Saccharomyces cerevisiae: analysis of the genes in the FUN38-MAK 1 6-
SP07 region. J Bacteriol 1 76 :  1 872- 1 880. 
86. Stnilfors A, Walfridsson J ,  Bhuiyan H,  Ekwall K (20 1 1 )  The FUN30 chromatin 
remodeler Fft3 protects centromeric and subtelomeric domains from 
euchromatin formation. PLoS Genet 7: e l 00 l 334. 
87.  Durand-Dubief M, Wil l  WR, Petrini E, Theodorou D, Harris RR, et al .  (20 1 2) 
SWIISNF-Like Chromatin Remodeling Factor Fun30 Supports Point 
Centromere Function in S. cerevisiae. PLoS Genet 8: e 1 002974. 
88. Ne es-Costa A, Wil l  WR, Vetter AT, Miller JR, Varga-Weisz P (2009) The 
SNF2-family member Fun30 promotes gene silencing in heterochromatic 
loc i .  PLoS One 4: e8 1 1 1 . 
89. Ouspenski II, Elledge SJ, Brinkley BR ( 1 999) New yeast genes important for 
chromosome integrity and segregation identified by dosage effects on 
genome stabi l i ty.  Nucleic Acids Res 27: 300 1 -3008. 
90. Costel loe T, Louge R, Tomimatsu N, Mukherjee B,  Martini E,  et al . (20 1 2) The 
yeast Fun30 and human S MARCAD 1 chromatin remodellers promote DNA 
end resection. Nature 489: 5 8 1 -584. 
9 1 .  Chen X, Cui D, Papusha A, Zhang X, Chu CD, et al .  (20 1 2) The Fun30 
nucleosome remodeller promotes resection of DNA double-strand break 
ends. Nature. 
92. Ubersax JA Woodbury EL, Quang PN, Paraz M, Blethrow JD, et al .  (2003) 
Targets of the cycl in-dependent kinase Cdk 1 .  Nature 425 : 859-864. 
93 . Schoor M, Schuster-Gossler K, Gossler A ( 1 993) The Etl- l gene encodes a 
nuclear protein differentially expressed during early mouse development. 
Dev Dyn 1 97 :  227-237. 
94. Mennoud JE, Rowbotham SP, Varga-Weisz PO (20 1 1 )  Keeping chromatin 
quiet: how nucleosome remodel ing restores heterochromatin after 
repl ication. Cell Cycle 1 0 : 40 1 7-4025 .  
6 3  
95 .  Aminin DL, Agafonova IG, Kal inin VI, Si lchenko AS Avi lov SA, et al . (2008) 
Immunomodulatory properties of frondoside A, a major triterpene glycoside 
from the orth Atlantic commercially harvested sea cucumber Cucumaria 
frondosa. J Med Food 1 1 : 443-453 .  
96. Aminin DL, Koy C Dmitrenok P S  Mul ler-H ilke B ,  Koczan D ,  e t  a l .  (2009) 
Immunomodulatory effects of holothurian triterpene glycosides on 
mammalian splenocytes determined by mass spectrometric proteome 
analy is. J Proteomics 72 : 886-906. 
97. Ferlay J Shin HR, Bray F, Forman D, Mathers C, et al. (20 1 0) Estimates of 
worldwide burden of cancer in 2008 : GLOBOCAN 2008. Int J Cancer 1 27 :  
2893-29 1 7. 
98 .  Blanco MA, Kang Y (20 1 1 )  Signaling pathways in breast cancer metastasis -
no el insights from functional genomics. Breast Cancer Res 1 3 :  206. 
99. Stevanovic A, Lee P, Wi1cken N (2006) Metastatic breast cancer. Aust Fam 
Physician 3 5 :  309-3 1 2 . 
1 00. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth 
of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572.  
1 0 1 .  Nguyen DX Bos PO, Massague J (2009) Metastasis: from dissemination to 
organ-specific colonization. Nat Rev Cancer 9: 274-284. 
1 02.  Bai J ,  Mei P, Zhang C, Chen F, Li  C, et al .  (20 1 3) BRG 1 is  a prognostic 
marker and potential therapeutic target in human breast cancer. PLoS One 
8: e59772. 
1 03 .  Roschke AV, Glebov OK, Lababidi S, Gehlhaus KS, Weinstein IN, et al . 
(2008) Chromosomal instabi l i ty is  associated with higher expression of 
genes impl icated in epithelial-mesenchymal transition, cancer invasiveness, 
and metastasis and with lower expression of genes involved in cell cycle 
checkpoints DNA repair, and chromatin maintenance. Neoplasia 1 0 : 1 222-
1 230. 
1 04. Cowper-Sal lari R, Zhang X, Wright JB, Bailey SD, Cole MD, et al .  (20 1 2) 
Breast cancer risk-associated SNPs modulate the affinity of chromatin for 
FOXA I and alter gene expression. Nat Genet 44: 1 1 9 1 - 1 1 98 .  
1 05 .  G irard M, Belanger J ,  ApSimon JW, Garneau FX,  Harvey C, et al .  ( 1 990) 
Frondoside A. A novel triterpene glycoside from the holothurians 
Cucumaria frondosa. Can J Chem 68 :  1 1 - 1 8 . 
64 
1 06. Li X Roginsky AB, Ding XZ Woodward C, Collin P, et a1. (2008) Review of 
the apoptosi pathways in pancreatic cancer and the anti-apoptotic effects of 
the novel ea cucumber compound, Frondoside A.  Ann N Y Acad Sci 1 1 38 :  
1 8 1 - 1 98 .  
1 07.  Jin JO, Shastina VV, hin SW, Xu Q, Park JI ,  et  al . (2009) Differential effects 
of triterpene glycosides, frondoside A and cucumarioside A2-2 isolated 
from ea cucumber on caspase activation and apoptosis of human leukemia 
cells. FEBS Lett 583 :  697-702. 
1 08 .  Artoub S,  Arafat K, Gelaude A, Al Sultan MA, Bracke M,  et a1. (20 1 3) 
Frondoside a suppressive effects on lung cancer survival, tumor growth, 
angiogenesis, invasion, and metastasis .  PLoS One 8 :  e53087. 
1 09. Al  Marzouqi N, Iratni R, Nernmar A, Arafat K, Ahmed Al Sultan M, et a1. 
(20 1 1 )  Frondoside A inhibits human breast cancer cell survival, migration, 
invasion and the growth of breast tumor xenografis. Eur J Pharmacol 668 : 
25-34.  
1 1  O .  McCloskey DE, Kaufmann SH, Prestigiacomo LJ,  Davidson NE ( 1 996) 
Pac1itaxel induces programmed cell death in MDA-MB-468 human breast 
cancer cells. Clin Cancer Res 2: 847-854. 
I l l . Zen K, Liu DQ, Guo YL, Wang C, Shan J,  et a1. (2008) CD44v4 is  a major E­
selectin l igand that mediates breast cancer cell transendothelial migration. 
P LoS One 3 :  e 1 826. 
1 1 2 .  Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M,  et al . 
( 1 995) E -cadherin is a tumour/invasion suppressor gene mutated in human 
lobular breast cancers. EMBO J 1 4 :  6 1 07-6 1 1 5 . 
1 1 3 .  Mohammadizadeh F, Ghasemibasir H ,  Rajabi  P, Naimi A, Eftekhari A, et a1 . 
(2009) Correlation of E-cadherin expressIOn and routine 
immunohistochemistry panel in breast invasive ductal carcinoma. Cancer 
Biomark 5 :  1 -8 .  
1 1 4. Kowalski PJ ,  Rubin MA, Kleer CG (2003) E-cadherin expression in primary 
carcinomas of the breast and i ts distant metastases. Breast Cancer Res 5 :  
R2 1 7-222. 
1 1 5 .  Boterberg T, Vennekens KM, Thienpont M, Mareel MM, Bracke ME (2000) 
Internalization of the E-cadherinlcatenin complex and scartering of human 
mammary carcinoma cells MCF-7/AZ after treatment w ith conditioned 
65 
medium from human skin squamous carcinoma cells COLO 1 6. Cell Adhes 
Commun 7: 299-3 1 0. 
66 
� � 4.......L ,:.p ".J� y,J (shRNA) .) .)�I .)�I . fARCAD l ..:....oUI �I � 'y .)c 
...s� ..}  %99 � J""l.io) � � • ./' IJ MARCAD 1 �J ,�I wts.....?J � ..j  IJ -.r."'..J' ..jJy}1 
. (SMARCAD l -shRNA3) J (SMARCADl -shRl�A l )  .)W\h....l\ .)�\ ..} fARCAD l w4PJY 
• .;JI .::WI � .h.:....,1 Iii. J SMARCAD 1 wl.¥ J.J! ..)c. Y--" ..;1 � v-:¥ w�1 w1.L) j.A ty.ll \41 ,,�) � 
. (control- hRNA) �)I I.$Jy.I\ �\ � 4*- ..»tJ\ 
..)c. .::WI � J F .)t:..J1 ylS:il JW J (' b1!';j �) (,j.l Y. SMARCAD 1 u,;.;J1 wts....J ,) .. Y' JJ)u u;,ul � 
01 o.fo. J ('.!ii c-iLillI .iI. ,� -ill.) � .Fl u,.. � �l....<:.c.)u IAJji:- J .::WI ;� 0;!ll1 .J4- I � wl� � 
.• ..Jl.,;.jj) J (,j.ill  0lb,r .)),.:. y>tS.J � � y...L....\ I.JY � fARC D 1 
' y'1S:il.l �lby-ll l.$.ill  y)),.:. oft. � �IJ )G.J.J u\).�';il wi .. }. ....... J �j.:J\ w�\ j.A o� t\yl � .)) 
.I.$.ill  0lby-l 4JWJ � u4)l.c wl�) J ,� �I I.$.lj� (,jillJ �I u,.. � 0hu... Jji:-J .J�'11 
oliJ U""" ' .r.Lo  J" ;S1 �J , ... �I .jU:a.J- � v .... y.ll ._yJ � ;S  I J <-U1 .:E I).� -.)U:..rJ t l ;S1 0--
..r .J\...:.:.j .'\ J I� o� � ...>-J y"\S:l.l _ I "# "::"'1�I "y'fo �..JA ..r -....:oyJl �1 �J.J.,...JI .� .Y-
� . IJ � )6..1I .J::>.!Y M RCAD l ( WL NF) u) .�I.o.:...o y1..S.j1 • ->- J � ).;L.- .'I J ""'� ,,�\ 
�Jyll .� � ¥)I � ..>F  Fun30 .�I �Jyl ...,L!...JI ... �1 ,=,:'�I � �. l ..)c .!..U....J ....J:' Jfill 
� �\,j.ll  J.!���I AJ! J ATP � j.W 4-i1 � wJ�IJ �"...y.lI '::"'�Jyll �lL � nfl .lly\ ...F' 
� o�l.;j ul J �I J� �' I ('J� Fun30 yt.....:J1 ,jfJJ./! J� · 1 ,�WI "::"'\"""I.J.llI "::"'�\ .l!  J .O 
� ul � �I Fun30 ,jfJJ./! �\ L..S 16 0  o';' J �tsJ J , - l..""'-""Jfill ..J:H Jfo... .. )'I ..)c )� F  30 
.Cyclin-dependent kina e (Cdk l )  dc2 �Y I � 
"-.icL.:...JI � �j)lJI '::"'li:JJyll � l.$�IJ Helicase .)c (j';":"': DEAD'H box .Yo M R 0 1 -.)) 
0:;J �lyJI � tSpl �I-"" J 01.,,:J1 c.J..o "::"'I).�) �.ll SMARCAD I . �  fij W �L.:.:.�L J C�)'I J (,;.\.....u.... I) 
.l.li.ll � t,} �.,......u J u� JS t,} �I SMARCAD 1 � ul ..)c J.l: �I u) . (u,uJy-,jfJJ./!) .::...li:JJyll 
.Yo J 4q22-q22m ('"... -"".fill t,} w� J SMARCAD 1 uc � Jy.....J1 � .J."..JI J .� \A I';""'" u� � ,,1......u:.11 
�I �.,s.JW p,)1 �I :� �AI �I..JA�I c.J..o .l.A.i u.,uy.lI .::...tj.J.,.J1 wl.}hJ1 J y-.S:ll .b� <.?'- �-"" 
.('.lll l.;:b. u\..1:..>'" J ,�I l:�1 u\..1:..>'" .<-L..J..JI 
.ill j u-Il �L.:.:.l .�I �� �I.,...J o.JJ'4--0 SMARCAD l lKlAA 1 1 2 � �1.ll1 .b1..,U.J)'1 �-"" ul , Ip.:,.. ¥I .l!J 
� .>'"  o.ll.;j c.J..o ....:&.J ,E 1 A-expressing l:�I .::...� t,} �,,; SMARCAD I � �AI l:)\.:J1 t,} ul k) 
.wtj.J.,...JI .� .J}:.:i 0 �)fol t,} I.JJ.l � SMARCAD I � t?1 wtj.J.,...J1 �y J:b. c.J..o .bt..::J1 
(ER)-negative MOA-MB-23 1 t� c.J..o �\..1:.y.J1 1.$.ill1 l::b. t,} UR-Jy....)'1 w� ul ,li� t,} u,....... � 
l::b. c.J..o l+i� uc J...j).iJl; SMARCAO I c.J..o I� �..JA tS';""'" � T47D J MXF-7 J (ER)-po itive J 
NHME - .. Lll .ill 1 . . � (j � 
u\..1:.y.J �AI l:�1 t,} SMARCAD l c.J..o '.l.l:>..A t� w�) y,o"\j t,} �I tSfi> ,�WI """ly � t,} 
tSpl � )lJ \A Jji:. J l:�1 0 fi>A' J ,l:�1 � J ,�I .J4-)'1 t,} �I J I.;�I YSli �.>'" c.J..o Jhil (j.ill  
.�Jy....)'1 w� 4..l �)k. '1 ufo t?1 (j.ill  u\..1:..>'" l::b. ('I�l-! 
t?IJ SMARTvector 2.0 Lentiviral :w.J 0,;Cy � (j.ill u\..1:..>'" l::b. .)c y,01il1 � ,J4--J1 1i-t. t,} 
� .4)1 l:�1 w� '1 t?1 SMART vector 2.0 c"r. � y,01il1 � �)I l:�1 .SMARCAD I � 
�YI u,uJyll J �J.J.J! .YoJ l.$� .l� .ly:..J! wfol J .� JS c.J..o ( 1 2- 1 0) c.J..o c"r.4-:)'1 tl........r.....)' 1  .Jt,u;.l 
4Gll U�J � �.;.b � ul�l; �I �4-:)'I l:�1 .i-t. Jih.:i � r-i (GFP positive clones) �l1J1 
oYlial l a JJpUl w IJLo�1  u..a� 
United Arab Emirates University 
College of Medicine 
and Health Sciences 
0HI.J � )'I � �I ($�I ul11.)'-" 4� o.,)J! � MARCAD l .).JJ 
c.S� 'II � 'JI .Jji;..J �I,r" '"  -.11 6J..fo.J 
�I ('..,wI � �WI �.J� � J� �� �.J.;bl 
(('�I �.J �I �.J�':II �) 
wly::.J � 
I-:-l� � /� 
201 3 .Jil.J:1 
© 
or) i D I I  a lJptJl w IJL.o�1  Cut.o� 
United Arab Emirates University 
College of Medicine 
and Health Sciences 
o�tJ � )'l � �l ��l 6\b.)'-" y� o..;J! � SMARCAD I -J,J..I 
c.S�'il � 'il ..Jji;...J �1.y·'j,,·Jl (.u..fo..J 
�I f'..,wl � �W\ �..;j � J� �� �-,.;bl 
(f'�1 rk-, �I �-,§il rk) 
wl�) � 
'-;-l..,.bc. � / j 
20 1 3 .Jily-
